Wantstats
IndustriesCompaniesCharts & Stats
Leads DBAdvisoryPricingContact us
Login
/Company Profiles

Deep Intelligence Across Industries

All CompaniesFortune 500Aerospace & Defense iconAerospace & DefenseAgricultureAutomotive iconAutomotiveFinancial Services iconFinancial ServicesChemicals & Materials iconChemicals & MaterialsConsumer Goods iconConsumer GoodsEnergy & Power iconEnergy & PowerEquipment & Machinery iconEquipment & MachineryFood & Beverages iconFood & BeveragesHealthcare & Pharma iconHealthcare & PharmaInformation Technology iconInformation TechnologyManufacturing & ConstructionMRO iconMROProfessional Services iconProfessional ServicesSemiconductors

Showing 14441 companies

Mexan

Mexan Limited

Premium
Information Technology

| Metric | FY2024 | FY2025 | FY2026 | |---|---|---|---| | Group employees at year end (headcount) | 157 | 113 | 21 | Mexan Limited is a Bermuda-incorporated, Hong Kong-listed investment holding company that has transformed from a hotel owner-operator into a cash-rich micro-cap with a small residual building-materials business. For almost two decades its principal asset was the 800-room Winland 800 Hotel in Tsing Yi, sold in April 2025 to a subsidiary of the Airport Authority Hong Kong for HK$765 million, crystallising a gain of roughly HK$400 million. The proceeds funded HK$473.9 million of special dividends and full repayment of bank debt. Today the operating business is Winland Firmstone Limited, which supplies imported kitchen cabinets, furniture, lighting, tiles, stone and other finishes and delivers design-and-fit-out projects, chiefly for Hong Kong property developers. Following the April 2026 exit of the Lun family controlling shareholder and a full board reconstitution, Mexan's investment case rests on its net cash, its listing status, and the as-yet-undisclosed strategic intentions of its new shareholder base and directors. --- ### Company's own description (paraphrased from AR FY2026) The company describes itself as an investment holding company whose group is principally engaged in supplying furniture and building materials and providing design and fit-out construction services, all through its wholly owned subsidiary Winland Firmstone Limited ("Winland Firmstone" or "WFSL"). It notes that it was also engaged in operating a hotel in Hong Kong, which was discontinued from April 2025. Winland Firmstone's core activities are described as: supply of imported kitchen cabinets, furniture and decorative lighting; supply of a wide range of building materials including ceramic tiles, mosaics, carpets and fabrics; supply of high-quality natural stone; and provision of design and construction services for fit-out projects. Management states that major customers include leading Hong Kong property developers (AR FY2026, MD&A pp. 4–6). The FY2025 report further specified that the kitchen cabinets supplied are imported European high-end products (AR FY2025, MD&A p. 6). ### Business model and revenue model | Revenue stream | Model type | Status | Evidence | |---|---|---|---| | Trading of furniture and building materials (kitchen cabinets, furniture, lighting, tiles, mosaics, carpets, fabrics, natural stone) | Product sale / distribution (import and resale) | Continuing | AR FY2026 | | Design and fit-out construction services | Project-based service / contract revenue (contract assets and liabilities recognised) | Continuing | AR FY2026 (contract assets HK$6.4m; contract liabilities HK$2.7m at 31 Mar 2026) | | Hotel operation (room lettings, F&B, laundry) | Service | Discontinued 2 April 2025 | AR FY2025; AR FY2026 | | Investment property holding (commercial property and leasehold land) | Asset holding; rental income not separately disclosed in sources reviewed | Continuing (non-core) | AR FY2026, Note 15 / KAM | | Interest income on cash deposits | Treasury | Continuing; HK$4.66m in FY2026 | AR FY2026 cash flow statement | Management attributed the FY2026 revenue increase to the final stage of fit-out projects, implying fit-out contract revenue was the dominant driver in FY2026 (AR FY2026, MD&A p. 6). There is no subscription or licensing revenue. ### Value chain position Winland Firmstone sits between overseas (principally European) manufacturers of premium kitchen systems, furniture, lighting and finishes and Hong Kong property developers and their main contractors. It acts as importer, specifier/distributor and, on fit-out packages, as a design-and-build sub-contractor. Purchases are partly settled in US dollars and euros while all revenue is in Hong Kong dollars, giving the business a structural foreign-exchange mismatch that is unhedged (AR FY2026, MD&A p. 9). ### Customer types and end-markets | Customer type | End-market | Concentration evidence | |---|---|---| | Hong Kong property developers (residential, including premium/luxury projects) | Hong Kong residential new-build and fit-out | Largest customer 65.5% and top five 87.3% of FY2026 revenue (FY2025: 25% and 56%) | | Main contractors on developer projects | Hong Kong construction | Not separately disclosed | | Former: hotel guests (leisure, business, long-stay) | Hong Kong hospitality | Hotel occupancy approx. 98% in FY2025 | Source: AR FY2026, Directors' Report p. 32; AR FY2025, Directors' Report p. 37 and MD&A p. 6. ### Independent characterisation On the evidence of the filings, Mexan is best characterised not as an operating company but as a listed cash shell with a small, highly concentrated, project-driven trading and fit-out business attached. Three observations support this. First, cash and short-term deposits of HK$197.9 million at 31 March 2026 are roughly 4.5 times FY2026 revenue and approximately 2.8–3.0 times the current market capitalisation. Second, the operating business is shrinking in real terms: continuing revenue fell from HK$102.5 million in FY2024 to HK$37.6 million in FY2025 before a partial, project-tail recovery to HK$44.1 million in FY2026, and management itself cautions that FY2026 margins reflect income from the final stage of legacy projects (AR FY2026, MD&A p. 4). Third, the change of control in April 2026 to a dispersed group of placees, followed by a board composed of directors with overlapping appointments at several other small-cap HKEX issuers, is a pattern associated with listing-platform repositioning rather than organic operating growth. The MD&A's reference to management being alert to opportunities in artificial intelligence, crypto and stablecoins (AR FY2026, MD&A p. 4) reinforces that the strategic direction is open-ended.

RevenueN/A
Employees21
Market CapN/A
Founded1991
Bermuda

Unlock Verified Contacts

Access verified employee contacts

Decision-maker information to support your sales, lead generation, and business development. 5 users, 5,500 credits a month with rollover, and one credit per contact email.

USD650/mo
Buy Now

Powering the world's best teams.
From next-gen startups to established enterprises.

Google logo
Amazon logo
Microsoft logo
Intel logo
Neste logo
McKinsey & Company logo

What our clients say

Trusted by forward-thinking businesses
for data-driven intelligence

Noah Malgeri
Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
MR
Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Joseph Aguayo
Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
BL
Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.
Peter Groot Koerkamp
Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.
Younghwan Choi
Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
MI
Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
RK
Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
JL
Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
AM
Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Wantstats logo

Move faster. Think smarter. Win bigger.

Join our data driven community.

© 2026 All rights reserved by Wantstats Research and Media Pvt Ltd

footer vector

Pages

  • About
  • News
  • Charts & Stats
  • Contact
  • Ecosystem pricing
  • Privacy policy

Address

Wantstats Research and media Pvt. Ltd, Office No 104, Pentagon 4,
Magarpatta City, Pune - 411028,
Maharashtra, India.

Contact

support@wantstats.com

Follow Us

Follow Wantstats on FacebookFollow Wantstats on InstagramFollow Wantstats on LinkedInFollow Wantstats on YouTubeFollow Wantstats on WhatsApp
MetroMining

Metro Mining Limited

Premium
Information Technology

| Metric | FY2024 | FY2025 | |---|---|---| | Employees (headcount) | 235 | 343 | | Bauxite Hills operating-season turnover (%) | 25 | 15 | | Average age (years) | 48 | 44 | Source: FY2025 Annual Report, Sustainability Report. Note: FY2024 turnover includes the wet season; FY2025 measures March–December only. Metro Mining is the only pure-play bauxite producer listed on the ASX, operating the 100%-owned Bauxite Hills Mine on the Skardon River in Western Cape York, about 95 km north of Weipa. It mines a high-alumina, direct-shipping bauxite, screens it, barges it down the Skardon River and transships it offshore through its Offshore Floating Terminal (OFT) *Ikamba* into Capesize and Panamax vessels bound almost entirely for Chinese alumina refineries. After four years of losses and a balance sheet that repeatedly needed going-concern support, a 2023–2024 brownfield expansion lifted nameplate capacity to about 7 Mtpa and delivered record shipments of 6.2 Mt and record underlying EBITDA of A$72.9 million in FY2025. Metro sits at the low end of the delivered cost curve into China because it is close to market and has fixed most of its freight. Its key exposures are seaborne bauxite pricing set by Guinea supply, Cape York weather, a single asset, and a concentrated Chinese customer base. --- ### What the company does Metro Mining explores for, mines, transships and sells bauxite, the ore from which alumina (and ultimately aluminium) is refined. Its principal activities during FY2025 were described in the FY2025 Directors' Report as exploration, mining, transhipping, sale of bauxite, and brownfield expansion of the Bauxite Hills Mine. In the 2026 Half-Year Report the expansion element was dropped from that list, signalling that the 7 Mtpa expansion is now treated as complete and the business is in steady-state operation and optimisation mode. ### Company's own description (paraphrased from the FY2025 Annual Report) Metro describes itself as an ASX-listed mining and exploration company based in Brisbane. Its flagship Bauxite Hills Mine sits about 95 km north of Weipa within a tenement package of roughly 810 km², and has operated since April 2018. At 31 December 2025 the mine carried an estimated Ore Reserve of 69.6 Mt and a total Mineral Resource of 107.4 Mt. Ore is shipped to Asia-Pacific markets where Cape York bauxite has a strong reputation. Metro also holds a portfolio of exploration projects in Cape York. Its stated vision is to be "the Premier Bauxite Supplier." Its purpose is to responsibly produce quality bauxite for customers while delivering value to customers and investors and sustainable benefits to Cape York. The Chair's letter characterises Metro as the only pure-play bauxite producer on the ASX. ### Business model and revenue model Metro's revenue model is 100% product sales of a single commodity. There is no service, subscription or licensing revenue. **Product:** Direct-shipping ore (DSO) high-alumina bauxite. It is screened on site but not beneficiated beyond screening, although dry-screening trials for silica upgrading were promoted to full-time production trials in Q3 2026. **Contract structure:** Sales go through binding offtake agreements and spot or trial cargoes. Pricing is agreed quarterly, roughly 4–6 weeks before each quarter starts (Q2 2026 Quarterly Report). Some historic contracts were fixed-price legacy agreements. These rolled off during 2025, so Metro has full exposure to market pricing from 2026 (FY2025 results commentary). **Incoterms:** Sales are made on either a CIF basis (Metro bears ocean freight and insurance) or an FOB basis from the Port of Skardon River. About 40% of FY2023 sales were FOB. **Payment terms:** Irrevocable letters of credit cover 90% of provisional cargo value. The balance, including quality bonuses or penalties, is settled after discharge and analysis in the destination port (FY2023 and FY2024 Financial Reports, Note 3). **Revenue recognition:** Point in time, when the bauxite is loaded onto the ocean-going vessel. **Freight hedging:** Contracts of Affreightment fix charter and bunker rates. About 80% of the 2026 offtake schedule is backed by long-term freight contracts agreed in 2025 (Q2 2026 Quarterly Report). **Currency hedging:** Revenue is USD-denominated and costs are largely AUD. The company runs an AUD/USD hedge book: US$165 million at an average of 0.64 at end-2025, and US$75 million at an average strike of 0.65 at 30 June 2026. ### Value-chain position Metro sits at the upstream raw-material end of the aluminium value chain: bauxite to alumina refinery to aluminium smelter to fabricators. It owns the mine, haul road, screening plant, Barge Loading Facility (BLF) and port stockpiles. It holds a 50% interest in the joint venture that owns the OFT *Ikamba*. Barging, floating-crane transhipment (*TSA Skardon*), mining equipment and much of the haulage are contracted. Key contractors include Transhipment Services Australia (TSA) for barges and the floating crane, and Blake Machinery Group for mining and haulage equipment. Metro does not refine alumina. ### Customer types and end-markets | Period | Disclosed customers | Number of customers = 100% of revenue | |---|---|---| | FY2023 | Shandong Xinfa Import & Export (Xinfa Group); Xiamen Xiangsen Aluminium; Shandong Lubei Enterprise Group | 3 | | FY2024 | Xinfa Aluminium Group; Xiamen Xiangsen Aluminum; Emirates Global Aluminium Group (UAE); Chalco Zibo International Trading; Shandong Lubei Enterprise Group | 5 | | FY2025 | Xinfa Aluminium Group; Xiamen Xiangsen Aluminum; Shandong Lubei Enterprise Group; Guangxi Longzhou Xinxiang Ecological Aluminum Industry | Not stated as a count in retrieved text; all sold to Chinese refineries | | 1H 2026 | Xinfa Aluminium Group; Shandong Lubei Enterprise Group; Hainan Sumec Supply Chain; Zhejiang Jinliantong International Trade | 4 | | 2H 2026 | Trial cargoes agreed with two new customers at market prices (names not disclosed) | n/a | Customers are alumina refiners and their trading arms, predominantly in Shandong, Guangxi and other refining provinces in China. In FY2024 the customer base briefly extended to the United Arab Emirates (Emirates Global Aluminium). Sources: FY2023, FY2024, FY2025 Annual Reports; 2026 Half-Year Report; Q2 2026 Quarterly Report. The ultimate end-market is aluminium demand: construction, transport, packaging, electrical transmission and renewables. The Chair's FY2025 letter explicitly frames bauxite as a core enabler for these sectors. ### Independent characterisation Metro is a small-cap, single-asset, single-product, seasonally constrained logistics business as much as a mining business. Its margin depends on four things: (1) the seaborne bauxite price into China, which Guinea now sets as the marginal supplier; (2) the AUD/USD rate; (3) freight, where Metro's short voyage and fixed contracts are a structural advantage; and (4) the reliability of a long, fragile supply chain (pit, haul road, screens, BLF, barges, river channel, OFT, ocean vessel) in a tropical environment with a wet season and cyclone risk. The FY2023–FY2025 turnaround came mainly from volume leverage over a largely fixed cost base after the expansion, not from structural price gains. The 1H 2026 underlying EBITDA loss of A$30.3 million shows how quickly earnings swing when a soft price coincides with the seasonal shutdown and a major dry-dock.

Revenue$0.2B
Employees343
Market CapN/A
Founded2006
Queensland, Australia
Metcash

Metcash Limited

Premium
Information Technology

Metcash is Australia's largest wholesaler, distributor and service platform for independent retailers. It operates across three pillars: **Food:** IGA, Foodland, Superior Food Services, Campbells and C-Store Distribution. **Liquor:** Australian Liquor Marketers and the IBA banners, including Cellarbrations, The Bottle-O, IGA Liquor, Porters Liquor and Thirsty Camel. **Hardware & Tools:** Total Tools and Hardware Group, including Mitre 10, Home Hardware and Total Tools. Its economic model is high-volume, low-margin warehouse distribution. FY26 EBIT margin was about 2.6% of revenue including charge-through. Metcash leverages a largely fixed distribution-centre cost base and earns supplier rebates, franchise fees, retail margins and, increasingly, digital and retail-media income. Management describes the strategy as "Winning with Independents". The aim is to give family-owned stores the buying scale of the vertically integrated chains (Woolworths, Coles, Endeavour, Bunnings) while keeping local ownership. Since FY20 the group has deliberately diversified away from tobacco-exposed grocery wholesale into foodservice, hardware/tools retail, owned stores and digital services. Wholesale fell from 91% of earnings in FY19 to 76% in FY26. --- ### The company's own description (FY26 Annual Report / Directors' Report) Metcash describes itself as Australia's leading wholesaler and service provider to independent businesses. Beyond integrated wholesaling and scaled logistics, it also acts as a retail banner owner, a large retailer, a franchisor and a retail media operator. It runs a low-cost distribution model intended to let independents compete against vertically integrated retail chains. Its core competencies are procurement, logistics, marketing, retail development, operational support and retail media. Major distribution centres operate in every mainland state. These are supplemented by smaller warehouses and a portfolio of company-operated and joint-venture stores (Source: FY26 Directors' Report, Operating and Financial Review §1). ### Business model and earnings mechanics **Warehouse leverage.** Metcash pushes large volumes through a distribution-centre network with a relatively fixed cost base. Profitability depends on: - volume throughput; - category mix; - the share of retailers' purchases sourced through Metcash ("teamwork"); - supplier support, through volumetric and other rebates. The FY26 Directors' Report identifies warehouse leverage as the key profit driver for both Metcash and its network. **Strategic buying gains.** Part of Metcash's earnings comes from inventory gains when suppliers or governments raise prices. Tobacco excise indexation is one example. The accelerated 5% annual tobacco excise increases ended in 2025, which removes a recurring buying gain. The AGM 2026 presentation estimates the net FY27 impact at about A$10m, weighted to 1H27. **Charge-through.** Suppliers deliver directly to retailers but invoice through Metcash, which earns a small fee and carries the credit risk. Charge-through was A$2.274bn in FY26, up from A$2.166bn in FY25. **Owned and JV retail.** Metcash owns and co-owns stores, predominantly in Hardware & Tools (Total Tools JV stores and IHG trade centres). This is expanding into Liquor (Steve's Liquor Warehouse) and, from Q4 FY26, Food (owned IGA/Foodland supermarkets). Retail made up 14.1% of group earnings in FY26, against 9.1% in FY20 (AGM 2026). **Franchising.** Total Tools operates as a franchise system with 130+ stores. Franchise fees and JV store revenue are both disclosed revenue lines. **Digital and services.** - Sorted, a B2B marketplace, transacted about A$5.9bn in FY26, roughly 30% of Metcash revenue. - LocalEyes, the retail-media network, earned A$20.5m in FY26 revenue from 760+ in-store screens. - Loyalty programs include IGA Rewards, Mitre 10 Mighty Rewards (2.0m members) and Total Tools Insider Rewards (2.6m+ members). ### Revenue model mix | FY26 earnings channel (share of group EBIT) | % | |---|---| | Wholesale (Food, Liquor, Hardware, Tools) | ~76 | | Retail (owned/JV hardware, tools, liquor and food stores) | ~14.1 | | Foodservice & Convenience | ~10.1 | Metcash does not report revenue by product/service/subscription/licensing category. The best available proxy is the AGM 2026 earnings split by revenue stream: Revenue is almost entirely product sales (wholesale and retail). Service-type income includes franchise fees, retail-media revenue, supplier services and marketing levies. It is not separately quantified at group level, apart from retail-media revenue (A$20.5m in FY26). ### Value-chain position, customers and end-markets | Dimension | Characterisation | |---|---| | Value-chain position | Mid-stream: between FMCG, liquor and hardware manufacturers or brand owners (~5,500 suppliers) and independent retailers, hospitality venues, foodservice operators and convenience/petrol chains | | Customer types | Independent supermarket owners, including multiple store owners such as Ritchies, Romeo Retail Group and Drakes; contract customers such as Australian United Retailers (FoodWorks banner); petrol and convenience operators (all majors, including BP and Ampol); QSR and corporate foodservice accounts; pubs, clubs, hotels and casinos (on-premise liquor); independent bottle shops; independent hardware stores; builders and trades (frame & truss, trade centres); Total Tools franchisees; and retail consumers through owned stores | | End-markets | Australian grocery (supermarkets and convenience), foodservice, packaged liquor and on-premise liquor, residential construction and renovation (trade and DIY hardware), professional tools; small New Zealand liquor exposure (Allied Retail Group retail; NZ wholesale being exited) | ### Independent characterisation In substance, Metcash is a scale-logistics and buying-group business. Its competitive position depends on keeping a fragmented customer base (independents) competitive enough that they keep buying through it. Its returns profile is attractive on capital: ROFE was 19.9% in FY26. This is because receivables and payables largely fund inventory. Net working capital was only A$429.3m against A$17.35bn of revenue. The business is, however, structurally low-margin. It is exposed to three things it does not control: - the health of its retailer network; - category disruption, most clearly the collapse of legal tobacco, with about A$1.8bn of tobacco sales lost since FY21 (2026 Annual Report, Chair's Report); - the residential construction cycle, which drives Hardware & Tools margins. The post-2020 strategy (Total Tools, Superior Food, Bianco, Alpine, owned retail, retail media) is best read as converting a pure wholesaler into a diversified "platform plus selective retail" model. That shift has so far raised capital intensity faster than earnings: - Underlying EBIT in FY26 (A$503.7m) is broadly where it was in FY23 (A$500.8m). - Shareholders' equity rose from A$1.09bn to A$1.72bn over the same period.

RevenueN/A
Employees13,951
Market CapN/A
Founded1927
Australia
MetalsX

Metals X Limited

Premium
Information Technology

Metals X Limited is Australia's largest tin producer by attributable output and one of very few Western-listed, pure-play producing tin companies. Its economic core is a 50% interest in the Bluestone Mines Tasmania Joint Venture (BMTJV), which owns and operates the Renison Tin Operation near Zeehan in north-west Tasmania — a mine with roughly a century of operating history and a 2026 Mineral Resource of 21.8 Mt at 1.38% Sn for 300.3 kt of contained tin (100% basis). The other half of the joint venture is held by interests associated with Chinese tin major Yunnan Tin. Metals X sells its share of tin-in-concentrate to Asian smelters and complements Renison with the Rentails tailings-retreatment growth project (final investment decision targeted after FEED completes in late 2026) and a portfolio of strategic equity stakes in tin and base-metal developers, including First Tin, Elementos and Stellar Resources. The company carries no corporate debt and held A$374 million of cash at 30 June 2026. --- ### What the company does Metals X is, in substance, a single-asset tin producer with an attached strategic investment portfolio. The company itself does not operate Renison; the BMTJV operating company runs the mine, and Metals X accounts for its 50% share of the joint operation (its share of revenue, costs, assets and liabilities) in its consolidated financial statements. The company's own description (H1 2026 Appendix 4D, directors' report) frames its activities as (i) its interest in the Renison Tin Operation through its 50% stake in Bluestone Mines Tasmania Joint Venture Pty Ltd, and (ii) investments in companies undertaking exploration and development of tin, gold and base metals projects in Australia (and, in practice, the UK and Hong Kong). ### Business and revenue model | Revenue component | Description | Approx. share of revenue | Source | |---|---|---|---| | Sale of tin-in-concentrate (Metals X 50% share) | Metals X independently markets and sells its 50% share of Renison concentrate to smelters under offtake/sales agreements; revenue is linked to the LME tin price, concentrate grade, treatment/refining terms and A$/US$ exchange rate | Effectively ~100% of operating revenue | FY2025 Appendix 4E; quarterly reports | | Interest income | Interest on cash balances (A$293.6m at Dec 2025; A$374.0m at Jun 2026) and on convertible notes issued by Cyprium Metals | Not separately disclosed in sources reviewed; classified as other income | Q1 CY2026 quarterly report | | Fair-value gains on investments | Mark-to-market movements on listed equity and convertible-note investments | Non-operating; material to profit in some periods (e.g., H1 2025) | H1 2025 Appendix 4D | | Share of associate results | Equity-accounted share of First Tin Plc (29.95%) | Non-operating | H1 2026 Appendix 4D | **Revenue model mix:** 100% product (commodity) revenue; no service, subscription or licensing revenue. Pricing is price-taker, commodity-linked, and denominated in US dollars before conversion to A$. ### Value chain position Metals X sits in the upstream segment of the tin value chain: underground mining, ore sorting, gravity/flotation concentration and production of tin-in-concentrate at Renison. It does not smelt or refine; concentrate is shipped to third-party smelters. Historical disclosures identify the buyers of its share as Thaisarco (Thailand) and MSC (Malaysia Smelting Corporation), and Metals X entered into an offtake agreement with joint-venture partner-affiliate Yunnan Tin Group for 2024 (International Tin Association report on the Q4 CY2023 quarterly). Downstream, refined tin is used predominantly in electronics solder, with additional demand from tinplate (packaging), chemicals, lead-acid batteries and emerging uses in energy-transition technologies. ### Customer types and end-markets | Customer type | Named counterparties (where disclosed) | End-markets ultimately served | |---|---|---| | Custom tin smelters | Thaisarco (Thailand), Malaysia Smelting Corporation (Malaysia), Yunnan Tin Group (China) | Electronics solder (semiconductors, PCBs, data centres, EVs), tinplate packaging, tin chemicals, batteries, solar PV ribbon | ### Independent characterisation Analytically, Metals X should be viewed as a leveraged, unhedged call on the tin price wrapped in a cash-rich holding company. Three features dominate the investment case. First, Renison is a high-grade (processed grade ~1.95–2.24% Sn in H1 2026), long-life underground operation in a tier-one jurisdiction — rare in a tin supply base dominated by China, Indonesia, Myanmar, Peru, the DRC and Bolivia. Second, the balance sheet is unusual for a miner of its size: A$374 million of cash at 30 June 2026 against a market capitalisation of roughly A$1.6 billion means cash represents over one-fifth of equity value. Third, management (led by Executive Director Brett Smith, a nominee associated with 23.3% shareholder APAC Resources) has pursued a "tin aggregator" strategy through minority equity stakes rather than dividends or buybacks, which creates both optionality and capital-allocation risk.

Revenue$0.2B
Employees175
Market CapN/A
Founded2004
South Perth, Australia
Metals

Metals Australia Ltd

Premium
Information Technology

Metals Australia is a Perth-headquartered, ASX-listed critical-minerals developer whose value now rests overwhelmingly on one asset: the 100%-owned Lac Carheil (formerly Lac Rainy) high-grade flake-graphite project near Fermont, Québec. The project is held through Canadian subsidiary Northern Resources Inc. In 2026 the company recast itself from a diversified junior explorer into a proposed vertically integrated "mine-to-anode" developer. An April 2026 Preliminary Economic Assessment (PEA) outlined a downstream Battery Anode Material (BAM) refinery at Baie-Comeau. A June 2026 Prefeasibility Study (PFS) declared a maiden Ore Reserve and a 24-year concentrate operation. The company quotes a combined pre-tax NPV8 of A$3.72bn for the two studies. That sits against a market capitalisation of only about A$13m and cash that fell to roughly A$3.7m (derived) by 30 June 2026. Secondary Australian assets (Manindi Ti-V-Fe and Zn-Cu-Ag, Warrego East Cu-Au, Corvette River Au in Québec) provide optionality. Funding over US$1.2bn of combined capex is the defining challenge. --- ### Company's own description In the FY2025 Annual Report, the company says its principal activity is the exploration for, and evaluation of, mineral deposits and mineral resource development. It describes itself as having a track record of critical-minerals discovery. It says it explores and develops a portfolio of advanced critical-minerals and metals projects in three Tier 1 jurisdictions: Western Australia, the Northern Territory and Québec, Canada. Note 1 of the financial statements describes the group's operations as mineral exploration and investment. ### Independent characterisation | Income type | FY2025 (A$) | Share of FY2025 income | |---|---|---| | Interest | 611,374 | about 34% | | Flow-through premium recognition (non-cash) | 966,633 | about 54% | | Canadian tax-credit refund | 204,431 | about 11% | | Total | 1,782,438 | 100% | The company is a single-asset-dominant, pre-development junior. It has no operating revenue, no product sales, no offtake contracts and no project finance. Its economic model is to: - create value through resource definition and engineering studies (Scoping in 2021, PFS in 2026, and a Final Feasibility Study (FFS) planned for 2026–27); - capture Québec and Canadian government support (refundable exploration tax credits, the C$600k PARIDM grant, applications to the Critical Minerals Infrastructure Fund, and Clean Technology Manufacturing investment tax credits); - monetise the asset through strategic partnering, offtake-linked financing, sale, or development funding. **Revenue model (current):** 100% non-operating. Source: FY2025 AR, Note 7 and income statement. There is no product, service, subscription or licensing revenue. **Prospective revenue model (per studies):** 1. Sale of flake-graphite concentrate (about 101kt pa at 95.4% Cg, per the 2026 PFS) into refractories, expandables and battery-feed markets. 2. Sale of coated spherical purified graphite (CSPG) battery anode material (more than 51kt pa, per the 2026 PEA) to lithium-ion cell manufacturers. The concentrate plant would supply the refinery internally. **Value-chain position:** Currently upstream exploration. The target is integrated upstream (mine and concentrator) plus midstream (anode-material refining). **Target customers and end-markets (prospective):** North American and global battery and EV supply chains seeking non-Chinese graphite. Secondary markets include industrial graphite and, for Manindi, high-grade iron ore with vanadium credits and TiO2 feedstock. ### Asset portfolio summary | Project | Location | Interest | Commodity | Stage | |---|---|---|---|---| | Lac Carheil Graphite (formerly Lac Rainy) | Fermont area, Côte-Nord, Québec | 100% | Flake graphite | PFS completed June 2026; maiden Ore Reserve; FFS next | | Quebec Anode Project (BAM Refinery) | Jean-Noël-Tessier industrial park, north of Baie-Comeau, Québec | 100% | Battery anode material (CSPG) | PEA completed April 2026; moving directly to FFS | | Corvette River (Felicie, East/West Eade) | James Bay, Québec | 100% | Au-Ag, Cu-Pb-Zn, Li | Early exploration | | Lac du Marcheur | Central Québec | 100% | Cu-Co | Early exploration (via a Canadian subsidiary) | | Manindi (incl. Manindi West VTM) | Murchison, WA | 80% | Ti-V-Fe (VTM); Zn-Cu-Ag resource | Discovery delineation; metallurgy | | Warrego East (EL32725 plus 3 applications) | Tennant Creek, NT | 80% (via Payne Gully Gold) | Cu-Au-Bi | First drilling completed in H2 CY2025 | | Warrambie | Pilbara, WA | 80% | Battery metals / Ni-Cu | Exploration | | Big Bell North | Murchison, WA | 80% (Payne Gully package) | Au | Soils and drilling | | Kimberley tenements M80/0106 and M80/0315 | Kimberley, WA | 3% free carry | Au (Butchers Creek, operated by WIN Metals) | Third-party resource | Sources: FY2025 AR; FY2024 AR; ASX announcements of 6 November 2025 and 28 April 2026.

RevenueN/A
Employees1
Market CapN/A
Founded1981
West Perth, Australia
MetalHawk

Metal Hawk Limited

Premium
Information Technology

Metal Hawk Limited is a Perth-based, ASX-listed greenfields gold explorer. After an extended period exploring for nickel, lithium, rare earths and gold across several Western Australian projects, it has become a single-asset discovery story. The flagship is the 100%-owned Leinster South Project, more than 430km² of under-explored tenure 10–40km south of Leinster on the southern tip of the Agnew–Wiluna greenstone belt. It lies between Gold Fields' Agnew–Lawlers operations and Northern Star's Thunderbox operation. Since rock-chip discoveries in August 2024 at Siberian Tiger, Thylacine and Tysons, drilling has progressed to the "Numbat lode" at Thylacine. In August 2026 the Numbat lode returned 9m at 12.3g/t Au from 70m, the project's best intercept to date. Metal Hawk has no revenue, no Mineral Resource and no debt. It funds itself through placements and asset sales, and holds equity stakes in Talonx Resources and Accelerate Resources received as sale consideration. It also has a newer pipeline asset, Mt Percy, on the Keith–Kilkenny Shear Zone. The investment case is pure exploration leverage, constrained by tight cash. --- **What the company does.** Metal Hawk acquires, explores and evaluates mineral tenements in Western Australia. Its stated objective is to "build shareholder value by making early-stage mineral discoveries through low-cost exploration" (FY2025 Annual Report). Its principal activity in FY2025 and H1 FY2026 was exploration and evaluation of WA tenements. Its core commodity is now gold. **Company's own characterisation (paraphrased from the FY2025 Annual Report and H1 FY2026 report).** - The company describes itself as a West Australian junior gold explorer. - It is focused on the Agnew–Lawlers region of the north-eastern Goldfields. - Leinster South is its flagship. - It has divested most non-core projects since the mid-2024 gold discovery so it can concentrate there. - The board presents the company as a "small, nimble team" focused on new discoveries rather than holding ground. **Business model.** This is a classic junior-explorer model: 1. Generate projects through ballots, pegging, options and low-cost acquisitions. 2. Use low-cost geochemistry and geophysics (rock chips, soils, drone/airborne magnetics, sub-audio magnetics, gravity) to define targets. 3. Drill-test the best targets (RC, then diamond). 4. Monetise value through either (a) defining a JORC Mineral Resource and pursuing development or corporate transactions, or (b) selling or farming out assets for cash or scrip. The company has used route (b) repeatedly. It earned scrip from Accelerate Resources (Kanowna East), Raptor Resources (Emu Lake) and Mount Burgess/Talonx (Viking, Blair North/Berehaven). Earlier it free-carried exploration under the Western Areas/IGO earn-in. **Revenue model.** Metal Hawk has no operating revenue. Its "other income" is interest, sundry items and gains on disposal of tenements. **Value-chain position.** Metal Hawk sits at the very top of the mining value chain: grassroots and early-stage exploration. It has no resource definition, studies, development, production, processing or marketing. Its "customers" are effectively: - equity investors who fund exploration; - potential acquirers or joint-venture partners, such as regional producers seeking ore feed or new discoveries. **End-markets.** The ultimate commodity end-market is gold, driven by investment, central-bank and jewellery demand. Historically the company also pursued battery and critical minerals (nickel sulphide, lithium, rare earths), but those projects have been impaired, relinquished or sold. **Independent characterisation.** Metal Hawk is a sub-A$15m, cash-constrained explorer whose value rests almost entirely on whether the Numbat/Thylacine system at Leinster South can grow into a coherent high-grade gold deposit. Its strategic pivot in 2024 was decisive and, judged by drilling results, technically rewarding. However, the share price has de-rated about 77% from the 41.5c FY2025 year-end level, as early drill results at Siberian Tiger and Thylacine did not immediately match the surface rock-chip grades. The September 2026 placement at 9.5c reflects that de-rating. Disciplined capital structure, roughly 12% board and management ownership and a portfolio of listed scrip are modest mitigants. Dilution risk and going-concern dependence are structural features of the model.

RevenueN/A
Employees3
Market CapN/A
Founded2018
with the new lease starting Nov, Australia
Meridian

Meridian Mining Plc

Premium
Information Technology

Meridian Mining plc is a London- and Toronto-listed, pre-revenue mine developer whose value rests almost entirely on the Cabaçal gold-copper-silver volcanogenic massive sulphide (VMS) project in Mato Grosso, Brazil — a historic past-producing mine the company acquired in 2020 and has since taken from exploration through a Pre-Feasibility Study (March 2025) to a Definitive Feasibility Study (September 2026). The DFS outlines a 13.9-year open-pit operation with an initial capex of USD 322 million, base-case after-tax NPV5 of USD 2.09 billion and 108% IRR, front-loaded by a high-grade starter zone that yields ~183,500 gold-equivalent ounces a year over the first five years. Meridian complements this "hub" with the Santa Helena satellite deposit and a 50 km VMS belt for "spoke" growth. With ~USD 96 million of cash at mid-2026, no debt, and fresh FTSE 250 and GDXJ index membership, it is positioned as a near-term developer approaching a project-finance and final-investment-decision inflection. --- **Company's own description.** In its H1 2026 interim management report, Meridian describes itself as a mineral resource development and exploration group with projects in Brazil, whose core asset base derives from a November 2020 purchase agreement covering rights within the Cabaçal Au-Cu-Ag VMS belt — including the historical Cabaçal mine and the separate Santa Helena Cu-Au-Ag-Zn-Pb mine — supplemented by additional licences across the belt and in the parallel Jauru and Araputanga greenstone belts. Non-core projects in Rondônia (notably Espigão) are retained. The stated vision is to create sustainable value by developing and exploring high-quality resource assets, as a responsible environmental steward building collaborative community and government partnerships. The company's "About Meridian" boilerplate (Sep 2026) lists four focus areas: (1) development and exploration of Cabaçal; (2) expanding the Santa Helena resource inventory; (3) regional-scale exploration of the Cabaçal VMS Belt to support the "Cabaçal Hub" strategy; and (4) exploration in the Jauru and Araputanga greenstone belts. **Independent characterisation.** Meridian is a single-asset, pre-production developer transitioning toward construction. It currently generates no revenue (FY2021–H1 2026 revenue: nil) and funds itself through equity; it reports one operating segment. Its intended business model, once Cabaçal is built, is that of a concentrate producer: ore will be processed on site into a clean, high-grade copper concentrate carrying payable gold and silver (plus some gravity-recovered gold), sold to smelters and traders under offtake contracts. Marketing work by Ocean Partners UK concluded that the concentrate would be attractive to smelters in Japan, South Korea and Europe, with Chinese smelters a lower-gold-payability alternative (DFS release, 22 Sep 2026). **Revenue model mix (projected, not current).** 100% product sales (metal-in-concentrate). No service, subscription or licensing revenue. By value at DFS base-case prices, gold dominates: LOM production of 983,537 oz Au, 180,634 t Cu and 1,779,720 oz Ag. At DFS base-case prices (USD 3,570/oz Au, USD 5.03/lb Cu, USD 50.17/oz Ag), gold represents roughly 60–65% of gross metal value and copper roughly 35–40% (analyst derivation from DFS production and price deck; payability and TC/RC deductions ignored). **Value-chain position.** Upstream: exploration → resource definition → mine development (current stage) → mining and concentration (from ~2028 per company timeline, subject to licensing and finance). Meridian does not intend to smelt or refine; concentrate will be sold downstream. Drilling, blasting, loading and haulage are planned to be fully outsourced. **Customer types and end-markets.** Prospective customers are custom copper smelters and concentrate traders. End-markets are the global gold market (investment, central bank, jewellery demand) and the copper market (electrification, power grids, construction, EVs).

RevenueN/A
Employees78
Market CapN/A
Founded2013
More London Riverside, United Kingdom
MercadoLibre

MercadoLibre, Inc.

Premium
Information Technology

MercadoLibre is Latin America's largest digital-commerce and fintech ecosystem and, by market value, one of the region's most valuable listed companies. Founded in a Buenos Aires garage in 1999 and now headquartered in Montevideo, it operates the region's leading marketplace by GMV across 18 countries and Mercado Pago, a fintech platform in eight countries that leads fintech MAUs in Argentina, Chile and Mexico and ranks second in Brazil. Its competitive moat rests on vertical integration: a proprietary logistics network (Mercado Envios) handling the majority of shipments through fulfillment centers, a first-party-data advertising business that has surpassed 10% of Latin American digital ad spend, and a credit engine underwritten on marketplace and payments behaviour. FY2025 revenue reached USD 28.9bn (+39%), with net income of USD 2.0bn. Under new CEO Ariel Szarfsztejn, the company is deliberately sacrificing near-term margin to deepen "ecosystemic" engagement via free shipping, credit cards, 1P, cross-border trade and the MELI+ loyalty programme. --- ### Company's own description (FY2025 10-K, Item 1, paraphrased with key terms) MercadoLibre describes itself as "the leading online commerce and fintech ecosystem in Latin America." Its e-commerce platform leads the region by GMV, and its fintech platform leads in MAUs among fintechs in Argentina, Chile and Mexico and is second-largest in Brazil. The marketplace is present in 18 countries (Argentina, Brazil, Mexico, Chile, Colombia, Peru, Uruguay, Venezuela — deconsolidated since December 2017 — Bolivia, Costa Rica, Dominican Republic, Ecuador, Guatemala, Honduras, Nicaragua, Panama, Paraguay, El Salvador). Mercado Pago operates in eight (Argentina, Brazil, Mexico, Chile, Colombia, Peru, Uruguay, Ecuador). The ecosystem comprises the Mercado Libre Marketplace, Mercado Pago, Mercado Envios (logistics), Mercado Ads, and Mercado Libre Classifieds. The company addresses a region of over 650 million people where e-commerce penetration of retail significantly lags the US, UK and China. ### Business model and revenue model | Stream | Sub-line | What it captures (10-K definitions) | FY2025 (USD m) | % of total | |---|---|---|---|---| | Commerce | Commerce services | Final value fees, flat fees, shipping & storage fees (net of carriers when acting as agent), classifieds fees, advertising, membership subscriptions, ancillary services | 12750 | 44.1 | | Commerce | Commerce product sales | First-party (1P) inventory sales and related shipping | 3544 | 12.3 | | Fintech | Financial services and income | Off-platform payment commissions, installment financing, interest on cash/investments held for Mercado Pago (net of pass-through yield in Brazil), debit-card commissions, insurtech fees | 6678 | 23.1 | | Fintech | Credit revenues | Interest on merchant/consumer loans; interest and commissions on Mercado Pago credit cards | 5858 | 20.3 | | Fintech | Fintech product sales | mPOS device sales | 63 | 0.2 | | Total | — | — | 28893 | 100.0 | The company reports two revenue streams: **Mix characterisation (calc.):** ~75% of revenue is transaction/fee/service-based (marketplace take-rate, shipping, ads, payments commissions), ~20% is interest-based (credit), ~12% is product sales (1P plus devices), and subscription (MELI+) revenue is embedded in commerce services and not separately disclosed. There is no material licensing revenue. ### Value-chain position MercadoLibre sits at the platform/intermediation layer between ~1 million+ active sellers (third-party, 3P, >90% of GMV per DEF 14A) and 100m+ unique buyers, while vertically integrating the three historically weakest links of Latin American e-commerce: trust/payments (Mercado Pago escrow and settlement), logistics (fulfillment centers handle "more than half of shipments"; dedicated aircraft, trucks and thousands of last-mile vans largely operated by third-party carriers), and credit (proprietary ML underwriting on ecosystem data). 1P retail is kept below 10% of GMV and used tactically for price competitiveness and assortment. ### Customer types and end-markets | Customer group | Products used | End-market | |---|---|---| | Consumers (buyers) | Marketplace, MELI+, Mercado Play, digital account, cards, loans, savings/AUM, insurance, crypto/Meli Dólar | Retail e-commerce; consumer banking | | SMEs / sellers (570k+ SMEs selling on marketplace; 9.5m+ entrepreneurs/SMEs in ecosystem — DEF 14A) | Listings, Mercado Envios fulfillment, Mercado Ads, merchant credit, Seller Assistant | Marketplace services; SME lending | | Offline merchants | Point (mPOS), QR, Tap to Phone, acquiring | Merchant acquiring | | Online merchants (incl. large enterprises) | Checkout, payment links, online payments | E-commerce payments processing | | Brands / advertisers | Product Ads, Brand Ads, Display, Video (on/off-platform) | Retail media / digital advertising | | Corporate buyers | B2B marketplace unit (launched Sep 2025, per press) | B2B procurement | ### Independent characterisation MercadoLibre is best understood not as a "Latin American Amazon" but as a hybrid of Amazon (marketplace + fulfillment + retail media), PayPal/Square (online and in-store acquiring) and a digital bank (cards, loans, deposits-like yield accounts), all operated off a single identity and data graph. The Q2'26 shareholder letter makes the economic thesis explicit: users active across both commerce and fintech ("ecosystemic users") grew 37% YoY, generated 70% more GMV and 55% more items per user than marketplace-only users, and produce contribution profit that is "multiples of the sum" of single-product users. The strategic bet, therefore, is engagement density rather than standalone segment margins — which explains management's willingness to compress consolidated operating margin from 14.6% (FY2023) to 6.7% (Q2'26).

RevenueN/A
Employees123,670
Market Cap$88.7B
Founded1999
Delaware, US
Memphasys

Memphasys Ltd

Premium
Information Technology

Memphasys is a micro-cap Australian reproductive-biotechnology company. After almost two decades of separation-science R&D, it has narrowed its focus to a single commercial asset: the patented Felix™ System. Felix is a benchtop console with a single-use cartridge. It uses electrophoresis and size-exclusion membranes to isolate viable sperm in about six to seven minutes, without the centrifugation used in conventional density-gradient and swim-up preparation. The business model is a classic razor/razor-blade model. Consoles are placed in IVF laboratories, and every procedure uses a cartridge, at a company-targeted price of A$80–150. After CE Mark (Dec 2025), TGA (Feb 2026), MHRA, Vietnamese, Thai and Turkish registrations, Memphasys has signed 11 public commercial agreements covering 31+ countries. These carry A$4.2m+ in announced multi-year contracted minimums, anchored by an exclusive national agreement with Monash IVF Group. Revenue is still very small (A$274k in FY2026). The balance sheet is fragile, with a going-concern material uncertainty, so Memphasys is best characterised as an early commercial-stage, single-product medtech that is highly dependent on external funding. --- ### Company's own description (paraphrased from the FY2026 Annual Report) The FY2026 Directors' Report describes Memphasys as an Australian reproductive biotechnology company focused on commercialising its patented Felix™ System for assisted reproduction. During FY2026 its stated activities were: rolling out Felix through contracted distribution and direct sales; progressing regulatory approvals; scaling manufacturing while lowering cartridge cost to expand margins; and enforcing a disciplined cost structure. The report states that Felix is the company's sole commercial priority. RoXsta™ and other complementary fertility diagnostics are kept as longer-term pipeline options. Note 1 of the financial statements keeps a broader legacy description: development and manufacture of cell and protein separation devices and consumables for healthcare, veterinary and biotechnology markets. ### Independent characterisation Memphasys is a pre-scale, single-product medical-device company in the IVF laboratory consumables niche. It has three defining features: 1. **Technology.** Felix replaces the two incumbent sperm-preparation methods, density gradient centrifugation (DGC) and swim-up (SU). These methods have changed little in roughly 40 years. They take about an hour and are linked to oxidative stress and sperm DNA damage. Felix's differentiation rests on speed (about 6–7 minutes), standardisation (it is automated, so results depend less on the operator), and gentleness (no centrifugation). 2. **Revenue model.** Revenue comes from (a) console sales or placements, which are paid consoles in some deals, for example "200 cartridges + 6 paid consoles" in Thailand, and (b) recurring single-use cartridges, one per procedure. Management targets A$80–150 per cartridge and "60%+ gross margin potential at target COGS" (Sep 2026 presentation). FY2026 direct costs roughly equalled revenue (A$273.5k vs A$273.8k), so gross margin is currently close to zero. 3. **Go-to-market.** Two channels: (i) direct sales to IVF groups (Monash IVF in Australia; UK clinics; CFA Italia), and (ii) exclusive in-country distributors with minimum purchase obligations (ITL for MENA and Turkey; TMSC in Vietnam; IVF Envimed in Thailand; TK Biotech in Poland; NOVIVITAE in the Nordics; INVIDO LAB in the Czech Republic, Slovakia and one further market; Andrology Center Coimbatore / Andro Diagnostics in India; Vitrolife subsidiaries in Japan, Canada and New Zealand). ### Revenue mix | Revenue type | FY2026 (A$) | Share of revenue | Source | |---|---|---|---| | Sale of Felix™ System (consoles and cartridges, recognised at a point in time) | 273,793 | 100% | FY2026 AR Note 5 | | Services / subscription / licensing | 0 | 0% | FY2026 AR Note 5 | | Memo: grant income (R&D Tax Incentive), not revenue | 384,175 | n/a | FY2026 AR Note 5 | | Memo: other income (gain on disposal, interest, misc.) | 48,977 | n/a | FY2026 AR Note 5 | The console/cartridge split is not publicly disclosed. Management says that recurring cartridge revenue is the strategic priority ("sole focus on annual recurring revenue (cartridge model)", April 2026 investor presentation). ### Value-chain position **R&D:** Conducted largely in partnership with the University of Newcastle (NSW) under Laureate Professor John Aitken (Scientific Director). Additional R&D was paused in FY2026. **Manufacturing:** Outsourced to third-party manufacturers (FY2024 AR). The names of the contract manufacturers are not publicly disclosed. A cloud-based inventory and operations platform was implemented in the June 2026 quarter. **Regulatory and quality:** Held in-house. The CE Mark under EU MDR is the regulatory "passport" used for reliance pathways in Australia, the UK, Qatar, India and elsewhere. **Distribution:** Mixed direct and distributor model (see 2.2). **End user:** IVF laboratory embryologists in fertility clinics. ### Customer types and end-markets | Customer type | Examples (disclosed) | End-market | |---|---|---| | Large corporate IVF networks | Monash IVF Group (22 Australian clinics); CFA Italia (Naples) | Human ART: IVF/ICSI | | Public / state hospital IVF units | Hamad Medical Corporation (Qatar's largest IVF institution) | Human ART | | Independent private fertility clinics | Four UK IVF groups in commercial evaluation; Japanese KOL clinics (Kobe, Reproduction Clinic Osaka, Kiba Park) | Human ART | | Specialist IVF distributors | ITL (MENA/Turkey), TMSC (Vietnam), IVF Envimed (Thailand), TK Biotech (Poland), NOVIVITAE (Nordics), INVIDO LAB (Central Europe), Vitrolife subsidiaries (Japan, Canada, NZ) | Human ART | | Animal breeding (pipeline, on hold) | Klean Gene Pty Ltd (adviser) | Livestock reproduction |

Revenue$0.0B
Employees28
Market CapN/A
Founded2006
Homebush West, Australia
Melco

Melco Resorts & Entertainment Limited

Premium
Information Technology

**Note on share count:** the 20-F cover reports 1,220,376,014 ordinary shares outstanding at 31 Dec 2025. This differs from the balance-sheet figure, likely because of shares held by the depositary or for share-plan purposes. The discrepancy is noted, not resolved. Source: FY2025 20-F, Item 6.D. Macrotrends shows 16,908 for 2024, which conflicts with the 20-F. The 20-F figure is preferred. Melco is the smallest-capitalised but most internationally diversified of Macau's six gaming concessionaires. It is a pure-play integrated-resort developer-operator whose earnings are anchored in Cotai through City of Dreams and Studio City. In FY2025, Macau generated about 86% of group Adjusted Property EBITDA (US$1.23bn of US$1.43bn). That made Melco a levered, high-beta proxy for Chinese premium-mass leisure spending. Since the 2022 concession re-tender, the company has repositioned toward premium mass: - VIP moved out of Altira in 2021 and out of Studio City in 2024. - Satellite casinos and Mocha venues closed in 2025. It has also built satellite growth platforms in Manila, Cyprus (Europe's largest IR) and, since August 2025, Sri Lanka. The investment debate centres on three questions: whether Melco can convert brand-led, design-intensive assets (Morpheus, Studio City Phase 2, the new REM hotel) into market-share and margin gains; whether it can keep deleveraging a balance sheet carrying about US$7bn of debt and a shareholders' deficit; and whether it can return capital through buybacks and eventually dividends. --- **Company's own description.** In its earnings releases and 20-F, Melco describes itself as a developer, owner and operator of integrated resort facilities in Asia and Europe. In Macau it operates City of Dreams (Cotai) and Altira Macau (Taipa). It operates the Mocha Clubs, which it describes as the only non-casino-based operation of electronic gaming machines in Macau. It also operates Studio City, a cinematically themed integrated resort in Cotai. Outside Macau: **Philippines:** it operates and manages City of Dreams Manila in Entertainment City. **Europe:** it operates City of Dreams Mediterranean in Limassol, Cyprus, plus licensed satellite casinos in other Cypriot cities. **South Asia:** it operates the casino and manages the Nüwa hotel at City of Dreams Sri Lanka in Colombo (Q2 2026 6-K, "About Melco Resorts"). **Business model.** Melco earns most of its revenue from casino win, recognised net of incentives, commissions and allocations for complimentaries. Hotel, food and beverage, entertainment and retail revenue support and diversify that core. The model is capital-intensive and works through government-granted rights: **Macau:** Melco Resorts (Macau) Limited holds one of six gaming concessions, running 1 January 2023 to 31 December 2032. Studio City Casino is run under the concession through the Studio City Casino Agreement. The concessionaire pays gaming taxes and costs from Studio City GGR and remits the residual to Studio City Entertainment. **Philippines:** City of Dreams Manila operates under a PAGCOR regular licence valid to 11 July 2033. The licence is co-held with the "Philippine Parties" (SM Investments, Belle Corporation and PremiumLeisure and Amusement), who receive payments under a cooperative arrangement. The land and buildings are leased from Belle. **Cyprus:** a 30-year licence granted June 2017, with 15 years of exclusivity, held through a 75%-owned subsidiary (ICR Cyprus / Integrated Casino Resorts Cyprus). **Sri Lanka:** a casino business licence from 1 April 2024 to 31 March 2044, held by Bluehaven Services. Melco operates in a resort developed by a John Keells Holdings subsidiary, paying casino rent and earning hotel management fees. **Revenue model mix (FY2025, from the Q4 2025 6-K income statement):** **Product (gaming service):** about 82%. **Service (hospitality):** about 18%. **Subscription and licensing:** nil. **Management fees:** Sri Lanka hotel management fees are immaterial and sit within "Other Operations". **Value-chain position.** Melco is a vertically integrated owner-operator. In Macau and Cotai it owns the land-concession rights and buildings and is the gaming licensee. It does not manufacture gaming equipment; suppliers include Aristocrat and other EGM vendors. Distribution runs through direct marketing, loyalty programmes and premium-direct VIP. Gaming promoters (junkets) remain only in reduced form outside Macau after Macau's 2022 law changes; the 20-F still lists dependence on gaming promoters as a risk. **Customer types:** **Premium-mass players:** the core profit pool in Macau. **Base-mass table and slot customers:** - Premium-direct rolling-chip (VIP) players: consolidated at City of Dreams Macau from late October 2024. **Non-gaming leisure guests:** hotel, entertainment, water parks, MICE. **Regional mass and local patrons:** in Manila, Cyprus and Colombo. **End-markets:** - Macau, the world's largest gaming market; 2025 GGR grew 9.1% per DICJ as cited in the 20-F. - Philippines (Entertainment City, Manila). - Republic of Cyprus and the Eastern Mediterranean tourist catchment, historically including Israel, Russia and the Middle East. - Sri Lanka (Colombo), with India the key feeder market. **Independent characterisation.** Melco is best understood as a Macau Cotai premium-mass operator with an option portfolio of smaller international resorts. Those resorts diversify cash flow at the margin but also raise operating complexity. In FY2025, non-Macau Property EBITDA was about US$196M (Manila US$132.8M, Cyprus US$68.2M, Sri Lanka −US$4.6M), roughly 14% of the group. The equity sits behind three layers of claims: corporate debt at Melco Resorts Finance, a separately financed and roughly 55%-owned Studio City silo, and noncontrolling interests. Equity value is therefore highly sensitive to Macau EBITDA. Analyst-derived TTM net debt / Adjusted EBITDA was about 4.8x at 30 June 2026.

Revenue$5.2B
Employees22,961
Market Cap$2.1B
Founded2004
United States, North America
Melbana

Melbana Energy Limited

Premium
Information Technology

Melbana Energy is a micro-cap Australian upstream oil and gas explorer. Its value has rested almost entirely on one asset: operatorship of, and a 30% interest in, the onshore Block 9 Production Sharing Contract (PSC) on Cuba's north coast. There the company discovered the stacked Amistad, Alameda and Marti oil-bearing sheets of the greater Alameda field. Between April and November 2025 the company briefly became a producer, building a crude inventory from the Alameda-2 well, but it never exported a cargo. Since late 2025, three shocks have pushed Block 9 into care and maintenance: - the Amistad-2 development well recovered no oil; - its 70% partner Sonangol defaulted on cash calls; - in June 2026 the US designated Cuba's state oil company CUPET a Specially Designated National. These shocks produced an FY2026 net loss of about A$50.2m and year-end cash of about A$0.47m. Melbana's remaining optionality lies in: - recovering money owed by Sonangol; - a pending reversion to 100% of Block 9; - low-cost Australian offshore exploration permits; - contingent payments and royalty from the Beehive prospect it sold to EOG. --- **Company's own description (AR2025):** Melbana describes itself as an Australian, ASX-listed independent oil and gas company. It says it holds a portfolio of exploration, appraisal and development-stage opportunities in Cuba and Australia. Its stated mission is to build a world-class exploration and production company by using its people's skills to identify and develop oil and gas opportunities. AR2023 framed the company as specialising in "high impact oil and gas exploration". It described the strategy as developing the Cuban discovery while bringing in partners to fund activity when needed. **Business model.** Melbana is a pre-revenue explorer and appraiser. AR2025 states that "the Company is pre-revenue". The model has four parts: 1. **Acreage capture and technical de-risking.** Melbana takes low-cost positions through government acreage releases or negotiated PSCs. Examples are Block 9 in 2015, AC/P70 under the 2020 acreage release, and WA-552-P under the 2022 acreage release. 2. **Farm-out or sale to well-funded partners.** Partners carry drilling costs. Examples: - Total and Santos funded the Beehive 3D seismic survey in 2018. - EOG bought WA-488-P in 2021 for US$7.5m upfront plus contingent payments. - Sonangol farmed into Block 9 in 2020, funding 85% of the first two exploration wells for a 70% interest. 3. **Operatorship recharge.** As operator of Block 9, Melbana recovered most corporate and technical costs from the joint operation. AR2025 notes that the FY2025 loss represented corporate support costs "as the majority of the costs are recovered from the Block 9 project". 4. **Intended transition to production revenue.** The plan was to sell Amistad crude (19° API) to traders and refiners. AR2025 says a "reliable export pathway" had been identified, but no cargo was sold. **Revenue mix.** Melbana has no product, service, subscription or licensing revenue. Income has come from three non-operating sources: - interest on cash (FY2025: A$171,871); - "other income" (FY2025: A$63,597; FY2024: A$7,894,246, whose nature was not detailed in the excerpts reviewed); - one-off asset sales (WA-488-P to EOG in 2021). **Value chain position.** Upstream only: exploration, appraisal and early development. There is no midstream, refining or marketing infrastructure beyond the wellsite tanks and tanker-loading gantries planned per pad (AR2025). **Customer types and end-markets.** These are prospective only: - international crude traders and refiners for Cuban crude (AR2025 notes the crude's middle-distillate content makes it attractive to "oil traders and refiners"); - in Australia, eventual gas and oil buyers, mainly through farm-in partners, if discoveries are made. **Independent characterisation.** Melbana is in practice a single-asset frontier-jurisdiction appraisal company. Its cost base is small (A$4–5m a year of corporate cost before recoveries). Its balance sheet was built on capitalised exploration (A$47.7m of exploration and evaluation assets at 30 June 2025). After the FY2026 impairment of A$35.7m and a A$10.7m inventory write-down, much of that book value has been removed. The company's investment case now turns less on geology than on four questions: - whether a sanctions-compliant operating structure in Cuba can be found; - whether Sonangol arrears can be recovered (US$23.5m in cash calls defaulted; a partial post-year-end receipt of $14.5m); - whether partners can be attracted to the Australian permits; - whether Beehive contingent payments materialise.

RevenueN/A
Employees6
Market CapN/A
Founded1994
Sydney, Australia
Meilleure

Meilleure Health International Industry Group Limited

Premium
Information Technology

Meilleure Health is a controlled, micro-cap Hong Kong holding company whose public identity is "health" but whose economic substance is overwhelmingly property and lending. Reported revenue in FY2025 was only HK$36.5m, of which rental income from PRC investment properties contributed more than half, while interest earned on a HK$491m loan book (HK$29.3m) was nearly as large as total gross profit [AR25]. Its healthcare activities — functional-medicine clinics in Shenzhen and Nanjing, the Jixiaojian medical-aesthetics-plus-skincare brand, the Swiss CBD brand AlpReleaf and minority stakes in cell-therapy developers Wingor Bio and Mei Ai Kang — generated HK$16.1m of revenue and a segment loss. A 109-unit townhouse project in Alphington, Melbourne began handing over units in H1 2026, lifting interim revenue nine-fold to HK$164.6m [IR26]. The shares trade at roughly 0.65x book, with the Zhou family controlling around 56–60% of the equity. --- ### The company's own description [AR25] defines the Group's principal activities as healthcare-related business, trading of construction materials and renewable energy products, real estate agency services, property investment and leasing, development of residential properties, and procurement services for renewable energy products. Management frames its long-run ambition around China's "Healthy China 2030" policy, with skin health management as the strategic anchor, cell therapy and health management as synergistic innovation areas, and a stated aspiration to move from selling health products to exporting health concepts. The corporate vision repeated in both [AR25] and [IR26] is "using technology and expertise to serve more people's health and beauty needs." ### Independent characterisation On the evidence of the financial statements, Meilleure Health is best characterised as a family-controlled investment holding company with four economic engines of very different weight: 1. **PRC investment property landlord** — HK$678.3m of investment properties at fair value (30 Jun 2026), all situated in the PRC and held on medium-term leases, generating HK$19.2m of rent in FY2025 (≈2.9% gross yield on the year-end fair value of HK$663.4m) [AR25], [IR26]. HK$509.1m of these properties are pledged to banks [IR26]. 2. **Lender** — a HK$441.2m loan book at 30 Jun 2026 (HK$491.2m at end-2025), more than half of which (HK$230.7m, 52.3%) is owed by U-light Energy (Guangyu Zhaoneng New Energy Group), a related party in which the Group holds 3.168%, at one-year LPR + 3.05% and guaranteed personally by the controlling shareholder; the remainder is unsecured short-term loans to eight independent borrowers at 3–8% [IR26]. Interest income (HK$29.3m in FY2025) exceeded rental income [AR25]. 3. **Residential developer (Australia)** — a wholly-owned 109-townhouse project on an 11,488 sq.m. site at 626 Heidelberg Road, Alphington, VIC (6.5 km from Melbourne CBD; GFA ≈18,752 sq.m.), marketed as "Yarrabend", built with Level 10 Pty Ltd and designed by Rothelowman; pre-sales started November 2022 and first-phase handovers began in H1 2026, producing HK$151.9m of property-sale revenue at a low (≈13%) gross margin [AR25], [IR26]. 4. **Healthcare and consumer health** — clinics, aesthetics services, skincare and CBD products (HK$16.1m revenue in FY2025; HK$4.4m in H1 2026), plus equity-accounted and FVTPL stakes in cell-therapy companies held within the "equity investment" segment [AR25], [IR26]. A residual trading business (construction materials, renewable-energy products and procurement services) has shrunk from HK$149m of revenue in FY2021 to HK$1.2m in FY2025 and HK$0.1m in H1 2026 [SA], [AR25], [IR26]. ### Revenue model mix | Revenue model (FY2025, HK$m) | Amount | Share of revenue | |---|---|---| | Lease/rental (recurring) — investment properties | 19.2 | 52.6% | | Product sales — healthcare-related products | 9.4 | 25.8% | | Services — aesthetic medical | 5.4 | 14.9% | | Services — healthcare management | 1.3 | 3.6% | | Agency/commission — healthcare product sale agency | 0.8 | 2.2% | | Services — renewable energy procurement | 0.4 | 1.0% | | Total revenue | 36.5 | 100.0% | Source: [AR25] Note 4. Note that interest income (HK$29.3m) and fair-value gains on investment properties (HK$21.7m) are recorded outside revenue but are central to the profit model. In H1 2026 the mix inverted: sale of completed properties (HK$151.9m) was 92.3% of revenue, rental 5.0%, healthcare 2.6% [IR26]. ### Value chain position, customers, end-markets **Property:** owner-landlord of PRC commercial units (several acquired from vehicles connected to the controlling shareholder, e.g., Yuye Tianyi Commercial Plaza units in Kunshan); developer-seller to retail homebuyers in Melbourne. **Lending:** provider of short-term working-capital loans to corporates and individuals sourced through management's networks [AR25]. **Healthcare:** downstream consumer-facing services (clinics, aesthetics) and branded consumer products sold through clinics, a medical-aesthetics chain partner (BeauCare Clinics), livestreamers on Taobao, Douyin and Xiaohongshu, and European distribution for AlpReleaf (22 countries) [AR25]. **Customers:** consumers (aesthetics, health management, CBD), PRC tenants (commercial leasing), Australian homebuyers, corporate borrowers; geographically 96% PRC in FY2025 revenue, shifting to Australia in 2026 [AR25], [IR26].

Revenue$0.0B
Employees43
Market Cap$0.1B
Founded1987
Admiralty, Hong Kong
Meghmani

Meghmani Organics Ltd.

Premium
Information Technology

Meghmani Organics Limited is an Ahmedabad-based, export-led, backward-integrated specialty and agro-chemicals manufacturer controlled by the second generation of the Patel–Soparkar founding families. Its economic engine is Crop Protection (~78% of FY26 standalone revenue), where it is among India's top-10 pesticide manufacturers, spanning intermediates, technicals and 40+ branded formulations, with a pyrethroid and 2,4-D herbicide franchise sold into Brazil, the US, Africa, Latin America and Europe. Its second pillar, Pigments (~22%), positions it among the top three global phthalocyanine pigment producers with an ~8% share and the largest CPC-blue producer. Two adjacencies — liquid nano-fertilisers (Meghmani Crop Nutrition) and titanium dioxide (Kilburn Chemicals, currently suspended) — represent its diversification bets, both being folded into the parent through a pending amalgamation. About 85% of revenue is exported to 75+ countries. The investment case today is a margin-recovery and deleveraging story in a cyclical, tariff-exposed industry. --- ### Company's own description In its latest disclosures (Q4 FY26 press release, 14 May 2026; Q1 FY27 press release, 29 July 2026), the company describes itself as "a fully integrated diversified chemical company with presence in Crop Protection, Crop Nutrition and Pigments." It states that it is amongst the top three global phthalocyanine-based pigment players with an 8% market share and amongst the top-10 manufacturers of pesticides in India with a presence across the entire value chain; that it has 40+ brands of pesticide formulations in India and a 400+ customer base across diverse industries; that it has a global presence in 75+ countries with a distribution network of 3,500+ distributors and dealers across India; and that ~85% of its topline comes from export markets (FY26). ### What the company does — independent characterisation MOL is fundamentally a B2B batch-chemistry manufacturer whose competitive identity rests on three attributes: 1. **Backward integration.** In agrochemicals it produces key pyrethroid intermediates in-house — cypermethric acid chloride (CMAC), meta-phenoxy benzaldehyde (MPBD) and meta-phenoxy benzyl alcohol (MPBAL) — which CRISIL (Apr 2026) credits with reducing import dependence and conferring a cost advantage. In pigments it is backward-integrated into crude copper phthalocyanine (CPC) blue, the base for Pigment Blue 15-series and Pigment Green 7/36. 2. **Off-patent, generic-molecule exposure.** The crop-protection portfolio is predominantly mature generic molecules (synthetic pyrethroid insecticides, 2,4-D herbicide) sold as technicals to global formulators/distributors and as branded formulations domestically. Value creation therefore depends on registrations (788 product registrations in FY25 vs 693 in FY23, per company disclosures summarised by Screener), cost position and capacity utilisation, rather than proprietary IP. 3. **Export dependence.** ~85% export share (FY26) versus ~80% (FY24) makes MOL highly exposed to US tariffs, Brazilian demand cycles, Chinese pricing and global channel inventory cycles. Management has historically noted that ~45% of crop-protection demand comes from the US and Brazil (investor presentations, Nov 2023 and May 2024). ### Business and revenue model | Dimension | Characterisation | |---|---| | Revenue model mix | ~100% product sales (manufacturing). No material service, subscription or licensing revenue. "Other operating revenue" (₹22.7 Cr in FY25 standalone, mainly export incentives/scrap) is incidental. | | Product vs service | Product: ~99%+ ; Service/licensing: nil disclosed | | Value-chain position | Mid-to-upstream: intermediates → technical-grade actives (AIs) → formulations (domestic branded). Pigments: crude CPC → finished phthalocyanine pigments. Crop nutrition: finished consumer-packaged nano liquid fertilisers. | | Customer types | (a) Global agrochemical majors and regional formulators/distributors buying technicals (export); (b) Indian farmers via 3,500+ distributors/dealers (branded formulations); (c) Printing ink, plastics, paints/coatings, textile, leather and rubber manufacturers (pigments; 400+ customers); (d) Fertiliser distribution channel and export buyers (nano fertilisers). | | End-markets | Global row-crop agriculture (soy, corn, cotton, cereals), non-crop (wood preservation, food-grain storage, public health), packaging/printing inks, plastics masterbatch, decorative and industrial paints, textiles. | | Seasonality | Domestic agro sales concentrated in Q2; overseas pigment sales skewed to Q4; 3–4 month export credit terms (CRISIL, Apr 2026). | | Working-capital intensity | High: cash conversion cycle ~110 days (FY26, Screener consolidated); working-capital limits enhanced to ₹700 Cr, ~77% utilised over 12 months to Feb 2026 (CRISIL). |

Revenue$0.3B
Employees1,234
Market Cap$0.2B
Founded1986
Gujarat, India
Megaport

Megaport Limited

Premium
Information Technology

Megaport began as a pure-play Network-as-a-Service (NaaS) provider: a software-defined, API-driven global fabric that lets enterprises provision private Layer-2/Layer-3 connections between data centres, public clouds (AWS, Azure, Google Cloud, Oracle, IBM, Alibaba), SaaS platforms and internet exchanges in minutes, billed monthly on demand. Between November 2025 and September 2026 it transformed itself into what management calls a "globally distributed automated infrastructure" and "AI inference cloud" platform. The acquisition of Latitude.sh added bare-metal CPU, GPU and storage infrastructure; Extreme IX established Megaport in India; and a run of long-term contracts with US AI companies lifted announced strategic total contract value to ~A$2.3B and pro forma Group ARR to ~A$1.1B. Megaport now combines a high-margin, capital-light connectivity franchise (Network ARR A$302.6M, NRR 116%) with a capital-intensive, contract-backed GPU compute business — a fundamentally different risk/return profile from the company of two years ago. --- ### Company's own description (FY26) In its FY26 materials Megaport describes itself as providing "private compute, network, and storage — globally, securely, and on demand" via a software-defined approach, enabling customers to build and scale infrastructure "in just a few clicks with a globally-distributed AI inference cloud," partnering with service providers, data centres and systems integrators across 1,100+ enabled locations (1,200+ by the 29 Sep 2026 announcement). The Megaport Network is ISO/IEC 27001 certified. (FY26 Results Announcement, "About Megaport".) The FY26 Investor Presentation frames the business as three pillars — Compute, Network, Storage — plus AI and Security overlays, orchestrated "via code" with no manual human intervention, across 31 countries, 330,000+ km of fibre routes, 3,000+ network devices and 13,000+ CPUs and GPUs deployed. ### Independent characterisation Megaport is now a two-engine business: 1. **Megaport Network (NaaS)** — the legacy core. Customers buy a physical Port (1/10/100/400 Gbps) in a Megaport-enabled data centre and then provision virtual services on top: Virtual Cross Connects (VXCs) to clouds or other data centres, Megaport Cloud Router (MCR) for virtual Layer-3 routing, Megaport Virtual Edge (MVE) for SD-WAN/NFV, Megaport Internet, Internet Exchange (IX) ports, NAT Gateway, firewall-as-a-service and DDoS protection. Revenue is recurring and usage-elastic, with a strong land-and-expand dynamic (NRR 114% at Jun 2026; 116% at Aug 2026). The business has high gross margins (~73% Group in FY26, with Network historically around 71–72%) because capacity is shared across thousands of customers; incremental cost is principally data-centre space/power, cross connects, dark fibre/bandwidth and partner commissions (12% of standalone Network revenue). 2. **Megaport Compute (Latitude.sh)** — acquired 26 Nov 2025. Provides on-demand bare-metal CPU servers, GPU servers (NVIDIA), virtual machines, Kubernetes and storage, plus, since April 2026, multi-year "strategic contracts" in which Megaport procures NVIDIA GPU, CPU, network and storage hardware for specific US AI/inference customers under fixed-term, take-or-pay contracts (36-month typical; weighted average just over four years for the September 2026 cohort). This is capital-intensive (FY27 capex guidance A$1.78–1.88B vs FY26 revenue of A$312M) and concentrated in North America (>85% of pro forma ARR). ### Revenue model mix | Revenue type | Description | FY26 weight (indicative) | |---|---|---| | Subscription / usage NaaS | Monthly recurring charges for Ports, VXCs, MCR, MVE, IX, Internet; term discounts | Network revenue A$268.3M = 86% of FY26 Group revenue | | On-demand Compute (IaaS) | Hourly/monthly bare-metal, GPU, VM rental via Latitude.sh | Majority of Compute revenue A$43.9M (FY26, 7 months of ownership) | | Contracted Compute (strategic contracts) | Multi-year committed revenue irrespective of usage; some prepayments | A$1.0M in FY26 (FY26 Investor Presentation); expected to dominate FY27 | | Storage | Object/block/file storage launched FY26 | Not separately disclosed | | Product / licensing | None material | — | ### Value chain position Megaport sits between (a) colocation/data-centre operators (Equinix, Digital Realty, NEXTDC, DataBank, etc.), from whom it leases space, power and cross-connects; (b) hyperscale clouds, for which it is an authorised interconnect partner (AWS Direct Connect, Azure ExpressRoute, Google Cloud Partner Interconnect, Oracle FastConnect, IBM Direct Link, Alibaba Express Connect); (c) hardware vendors (NVIDIA GPUs; network equipment), and (d) end customers. It does not own data centres or long-haul fibre; it is an asset-light orchestration layer on the network side and an asset-heavy owner of servers/GPUs on the compute side. ### Customers and end-markets **Network:** 3,206 customer logos and 725 "Large Customers" (≥A$100k ARR) at 30 Jun 2026 (FY26 Results). Segments include enterprises (financial services, media, healthcare, retail), cloud and SaaS providers, managed service providers/system integrators, carriers and content providers. Dedicated "exchanges" target financial services, AI providers (AI Exchange, 30+ providers per FY25 Annual Report) and voice/video. **Compute:** AI inference providers, developer-tooling/agentic AI companies, US-based technology providers backed by institutional investors, and (from Sep 2026) a publicly listed enterprise running its own AI workloads. Customer identities are not disclosed (29 Sep 2026 announcement). **Geography:** Network ARR at Jun 2026 — Americas ~A$166M, APAC ~A$77M (incl. India), EMEA ~A$47M (FY26 Investor Presentation chart). Pro forma Group ARR >85% North America (29 Sep 2026).

Revenue$0.2B
Employees311
Market CapN/A
Founded2013
Fortitude Valley, Australia
MegadoGold

Megado Gold Limited

Premium
Information Technology

Megado Minerals is a micro-cap ASX exploration company that has turned itself into a European base- and precious-metals explorer. Its flagship is an 80% interest in the Iberian Copper Project. This covers about 777 km² of Oligocene "red-bed"/Lisbon Valley-style sediment-hosted copper terrain across Navarra and Aragón in northern Spain, with at least 12 historic copper mines. Maiden diamond drilling began on 14 July 2026. The first hole returned narrow copper-silver mineralisation (0.55 m at 0.84% Cu and 11 g/t Ag). Megado also holds a five-year option over 80% of the Alpartir silver-copper-antimony vein project (576 km², Aragón). This option is subject to a shareholder vote and involves related-party vendors. Its legacy assets are two James Bay (Québec) lithium/gold claim blocks, and the North Fork rare-earths project in Idaho, which is optioned to Iluka Resources. The company has no revenue and about A$2.0m in cash, and it depends on equity funding. Its stated investment case rests on the EU's push for domestic critical raw materials. --- **Company's own description.** In its Directors' Reports, Megado describes itself as an ASX-listed mineral exploration company with a portfolio of exploration assets intended to underpin growth. It says it focuses on adding value through cost-effective exploration and discovery (FY2024 Annual Report; Interim Report 30 Jun 2026). Its standard announcement boilerplate in 2025 said it was targeting critical minerals and gold in the EU and Canada (Quarterly Activities Report, Sep 2025). **Independent characterisation.** Megado is a project-generator-style junior explorer. It does not produce, sell or license anything, and it has no customers. Its economic model works like this: 1. It acquires early-stage mineral rights cheaply, mostly for scrip plus performance rights tied to resource milestones. 2. It spends modest equity-funded sums on mapping, geochemistry, geophysics and drilling to raise the perceived value of those rights. 3. It then realises value through one of three routes: (a) a discovery large enough to re-rate the shares or attract a major; (b) a farm-out or option to a larger company, as with Iluka at North Fork; or (c) an outright sale. Its value-chain position is the very first link of the mining value chain, namely greenfield/brownfield exploration. Its "end-markets" are indirect. If successful, its copper and silver would feed European smelting and electrification demand. Its lithium would feed battery supply chains, and its rare earths would feed permanent-magnet supply chains. **Revenue model mix.** Product 0%, service 0%, subscription 0%, licensing 0%. The only income is bank interest: - A$9,585 in FY2024 and A$25,504 in FY2023 (FY2024 Annual Report) - A$7,479 in H1 2026 (Interim Report 30 Jun 2026) Non-recurring cash receipts have come from monetising assets. The main example is the A$670,759 first-tranche payment from Iluka's subsidiary for exclusive exploration rights at North Fork, received 13 February 2025 and booked against the asset rather than through revenue (FY2024 Annual Report, Notes 6–7; Interim Report 30 Jun 2026 cash flow comparative). **Customer types.** None. The relevant counterparties are: - equity investors (sophisticated and institutional placees), - potential acquirers or farm-in partners (e.g., Iluka Resources), and - host governments (Spain's Navarra and Aragón regional mining authorities, Québec's claim registry, the US Bureau of Land Management). **Operating model.** The company is very lean, with a small Spanish field and technical team. Core is logged at a Spanish project office. Geophysics, assaying and drilling are contracted out to Xcalibur, IGT, ALS, SGS and drilling contractors. Corporate administration is run from Perth.

RevenueN/A
Employees3
Market CapN/A
Founded2019
Perth, Australia
Medlab

Medlab Clinical Limited

Premium
Information Technology

Medlab Clinical was an Australian clinical-stage biotechnology company. It began as a research-driven, practitioner-only nutraceutical business. From about 2018 to 2022 it repositioned around NanoCelle®, its patented sub-micron delivery platform for oro-buccal, intranasal and transdermal administration. The lead asset was NanaBis™, a 1:1 synthetic CBD and dronabinol buccal spray targeting cancer-induced bone pain as an opioid-sparing therapy. NanaBis was available under Australia's Special Access Scheme and the UK named-patient programme, and was preparing for a multinational Phase III trial. The company sold its Australian nutraceutical business to PharmaCare in November 2021 to fund that pivot. It then attempted a Nasdaq dual listing, which collapsed in January 2023 into a funding crisis. Trading was suspended, most staff were retrenched, the core IP was sold to the founder for a contingent royalty, and the company sought a reverse takeover into strategic minerals. That deal was not completed, and the entity was delisted in February 2025. Today it is a non-operating shell with no disclosed business. --- ### Company's own description (latest disclosures) The FY2024 Annual Report (lodged 4 Nov 2024) no longer describes an operating business. It states that ASX suspended trading on 27 February 2023. Hall Chadwick was engaged as external consultants for an informal workout. The company retrenched most of its workforce and operated in a care-and-maintenance capacity while the directors devised a corporate restructure. Note 3 (Operating segments) records that, after the nutraceuticals business was discontinued in FY2022, the group had a single segment. The note also says the group "does not have any products/services it derives revenue from" (FY2024 AR, Note 3). The last full description of an operating business is in the October 2022 F-1. There the company called itself an Australian biotechnology company that develops fixed-dose combinations of the NanoCelle® delivery platform with active pharmaceutical ingredients (APIs). It stated an aim to disrupt the delivery-platform market for pain and mental-health pharmaceuticals, and a revenue strategy built on licensing its IP and assets to large established companies. ### Business model and revenue model (historical) | Model element | FY2015–FY2021 (pre-pivot) | FY2022–FY2023 (pharma pivot) | FY2024 onward (shell) | |---|---|---|---| | Primary activity | Practitioner-only nutraceuticals (34 formulations by 2019) plus clinical research | NanoCelle®-based drug development (NanaBis, NanoCBD, MDC2000), real-world evidence under SAS / named-patient access | Care and maintenance; search for a reverse-takeover asset | | Revenue type | Product sales through pharmacy wholesale (API/Priceline, TerryWhite Chemmart, Symbion), mostly practitioner channel | Product sales of NanaBis/NanoCBD under SAS; royalties and licence fees (PharmaCare, Cultech, YesHealth, American Nutritional Corp) | Residual pharmaceutical sales of A$11,894 in FY2024; contingent 20% royalty to "Entitled Shareholders" from Dr Hall (paid directly to shareholders, not to the company) | | Product / service / licensing mix | Mostly product | Mixed product plus licensing; licensing was the stated strategic priority | None | | Non-operating funding | Equity placements; R&D Tax Incentive refunds | R&D Tax Incentive (A$2.87M recognised FY2023); grants | Debt forgiveness (A$0.09M); Hall Chadwick fees accrued against future equity | ### Value-chain position Medlab was an asset-light IP owner and developer. The F-1 states it had no in-house manufacturing and relied on third parties. Those included Renaissance Lakewood LLC (US CDMO, FDA/DEA experienced), Natural Factors (Canada, TGA-approved), Extractas (formerly Tasmanian Alkaloids), and Purisys LLC (Georgia, US) for biosynthetic CBD and dronabinol with FDA Drug Master Files. It did own an OGTR-registered laboratory in Sydney, where NanoCelle was developed, and handled formulation, clinical design, regulatory filings and real-world-evidence collection itself. ### Customer types and end-markets **Prescribers and patients:** Australian doctors prescribing under the TGA Special Access Scheme; UK prescribers under the MHRA named-patient programme. More than 1,000 Australian patients were under clinical management on NanaBis by 2022 (Stockhead, Q3 FY2022 update), and over 1,200 by July 2022 (Q4 FY2022 4C). **Pharmacy and practitioner channel (until Nov 2021):** integrative-medicine practitioners and community pharmacy banner groups. **Licensees and distributors:** PharmaCare (Australia/NZ), Cultech (UK), YesHealth (Malaysia/Vietnam/Singapore), American Nutritional Corporation (US, NuScripts private label), Mega Lifesciences (heads of agreement for NanaBis global distribution). **Therapeutic end-markets:** cancer-induced bone pain and neuropathic pain, occupational stress and mild chronic pain, major depressive disorder, gut health, diabetes and obesity (exploratory), allergies, and nasal nucleic-acid vaccines (pre-clinical). ### Independent characterisation Medlab was a sub-scale, founder-led micro-cap biotech. It tried to bridge a cash-generating consumer-health business and a capital-hungry regulated-drug pipeline, and ultimately could do neither. The PharmaCare divestment (A$1.6M cash, per the F-1) removed most recurring revenue just as Phase III and FDA costs were set to rise. The company then depended on a single external financing event, the Nasdaq IPO, which failed amid a hostile biotech funding market in late 2022. The platform thesis (NanoCelle sub-micron buccal delivery) had real IP: patents granted in the US, Europe, Australia and other jurisdictions to 2036. But it never produced a registered (approved) prescription medicine, a pivotal efficacy readout, or a licensing deal with a large pharmaceutical company. The entity's endgame, a related-party sale of the IP to the founder for a contingent royalty followed by a failed minerals RTO, is typical of ASX shell outcomes for failed micro-cap biotechs.

RevenueN/A
Employees78
Market CapN/A
Founded2012
Alexandria, Australia
Medicskin

Medicskin Holdings Limited

Premium
Information Technology

Medicskin Holdings is a micro-cap, founder-controlled medical aesthetics and dermatology clinic operator. All of its revenue comes from Hong Kong. It runs two doctor-led "Medicskin" medical skincare centres in prime locations: a full floor at New World Tower in Central and a centre at Ocean Centre in Tsim Sha Tsui. These are supported by the complementary "facematter" treatment and skincare brand and a small anti-ageing and preventive-medicine offering. FY2026 revenue was HK$47.9 million. Of this, 81.8% came from prepaid courses of non-invasive and minimally invasive treatments: injectables, energy-based devices, HIFU and thread lifts. The group's main differentiators are its physician-performed model, anchored by a founder-dermatologist with more than 30 years in medical aesthetics, and a loyal client base (most clients have used its services for over five years). Its main constraints are scale and structure. It is about 1/20th the size of Perfect Medical and about 1/80th the size of EC Healthcare. It has a heavy fixed-cost base, thin equity of HK$5.2 million, and a persistent net current liability position caused by HK$23.2 million of customer prepayments. FY2026 marked a return to a small profit after three loss-making years. --- ### Company's own description (latest annual report) In AR26 the company describes itself as a medical skincare service provider in Hong Kong. Its "Medicskin"-branded centres are strategically located in New World Tower, Central (a core business hub) and Ocean Centre, Tsim Sha Tsui (a prime shopping district with harbour views). Medicskin specialises in medical skincare services provided by registered medical practitioners. The "facematter" brand offers medical aesthetic and lifestyle beauty treatments that complement Medicskin. Facematter skincare products are sold through the group's own online shop and a third-party shopping platform [AR26]. Clinical focus covers two areas [AR26]: **Medical dermatology:** acne, pigmentation, rosacea, dermatitis, eczema and warts. **Aesthetic improvement:** skin rejuvenation, facial sculpting, body contouring, acne scars and enlarged pores, removal of undesirable naevi (moles), and hair removal. The company states that most clients are long-term clients who have patronised the group for more than five years [AR26]. ### Revenue model Revenue is generated through three disclosed service lines, all within a single reportable operating segment [AR26]: 1. **Medical consultation services:** private consultations for examination and diagnosis of skin conditions, with recommendations of skincare products or treatments. Recognised over time as the service is provided. FY2026: HK$954k (2.0% of revenue). 2. **Prescription and dispensing services:** prescription and dispensing of pharmaceutical products, medication and skincare products, including retail skincare sales. Recognised at a point in time when goods are collected or delivered. FY2026: HK$7,778k (16.2%). 3. **Treatment services:** non-invasive and minimally invasive procedures. These typically involve injection of botulinum toxin type A and hyaluronic acid, cauterisation, thread lifting, and device-based treatments using laser, radio-frequency (RF), high-intensity focused ultrasound (HIFU) and high-intensity facial electrical stimulation (HIFES). FY2026: HK$39,139k (81.8%). **Prepaid package mechanics.** Treatment services are mostly sold as prepaid treatment packages. Cash received is deferred as a contract liability and recognised as revenue when treatments are delivered (an output method). Unused portions ("breakage") are recognised when the likelihood of redemption becomes remote, or in full when the package's service period expires [AR26]. At 31 March 2026, contract liabilities were HK$23.2 million. That is about 48% of annual revenue, and management expects it to be recognised over 12–36 months [AR26]. ### Value chain position Medicskin is a downstream, consumer-facing clinical service provider. It buys pharmaceuticals, injectables, skincare products, treatment consumables and capital equipment from suppliers. In FY2026 it bought from 76 Hong Kong suppliers, 3 US suppliers and 1 Korean supplier [AR26]. Pharmaceuticals come only from licensed Hong Kong drug distributors. Supplier concentration is meaningful. The largest supplier accounted for 18.5% of purchases and the top five for 56.3% (FY2025: 18.2% and 61.0%) [AR26]. Treatment devices are selected by the group's doctors and must be approved by the US FDA or Korea's MFDS, be CE-marked, or be supported by independent medical journals and clinical data [AR26]. The group does not manufacture. Facematter products are described as developed by a team with more than 20 years in cosmeceuticals [WEB]. Whether manufacturing is outsourced, and to whom, is not publicly disclosed. ### Customer types and end-markets **Customers:** individual retail consumers, overwhelmingly in Hong Kong. Customer concentration is negligible: the top five customers were under 4.4% of revenue (FY2025: 3.4%), and no customer exceeded 10% [AR26]. **End-markets:** - Hong Kong medical aesthetics, the core market. - Medical dermatology, the clinical niche. - Professional skincare retail, through the facematter e-shop. - Anti-ageing and preventive medicine: personalised wellness plans, genetic testing, and anti-ageing medicine and supplements [WEB]. **Geography:** 100% of external revenue comes from Hong Kong [AR26]. ### Independent characterisation Medicskin is effectively a two-clinic, owner-physician practice wrapped in a listed holding structure. The economic engine is three things working together: - the founder's clinical reputation; - a loyal, mature client base that buys prepaid treatment courses; - periodic refresh of the device and injectable menu (FY2026: Ultherapy PRIME®) to keep existing clients spending. The model has attractive unit-level features: - about 81% gross margin after consumables and products; - customer prepayments that fund working capital; - negligible receivables. It is, however, burdened by structurally high fixed costs: - staff costs were 47.6% of revenue in FY2026; - prime-location rent (right-of-use depreciation plus lease interest) was about 12.4% of revenue; - directors' emoluments alone were 18.2% of revenue. The result is extreme operating leverage. A swing of roughly ±5% in revenue moves the group between profit and loss. The company has a stated ambition to expand in Hong Kong and Mainland China [AR26][WEB]. In practice it has done the opposite: it disposed of a dormant Guangzhou subsidiary in FY2026 and has kept the same two-centre footprint. Its listed status adds compliance costs (audit fee HK$420k, plus GEM governance overhead) that are large relative to its earnings.

Revenue$0.0B
Employees42
Market CapN/A
Founded2000
Grand Cayman, Cayman Islands
Medical

Medical Developments International Limited

Premium
Information Technology

Medical Developments International is a Melbourne-based specialty pharmaceutical and medical device company. Its value rests on one proprietary asset, Penthrox (inhaled methoxyflurane), a fast-acting, non-opioid, self-administered analgesic for trauma and procedural pain, which it manufactures in Scoresby and Springvale, Victoria. Penthrox is the standard of care across Australian ambulance services and is gaining ground in hospital emergency departments. It is sold through partners in the UK, Ireland, the Nordics, France, Switzerland, Canada and more than 20 other markets. A second segment, Respiratory, sells asthma and COPD spacers, peak flow meters, nebulisers and masks in Australia and the US. After a costly FY21–FY24 phase of direct-market expansion, US FDA ambitions, China trials and A$16.4m of impairments, management under CEO Brent MacGregor reset the business to a capital-light, partner-led model with price discipline. The result was EBITDA-positive FY25 and FY26, free cash flow of A$4.2m in FY26, A$21.4m of cash and no debt. The investment case now depends on whether paediatric-label approval in Europe and emergency-department adoption can accelerate volume. --- ### Company's own description (latest annual report, FY26) In its FY26 Directors' Report, MVP describes its principal activity as providing emergency medical solutions aimed at better patient outcomes in Australia and overseas. It manufactures and distributes Penthrox, a fast-acting trauma and emergency pain relief product used in hospital emergency departments, ambulance services and sports medicine, and for analgesia during short surgical procedures. It also distributes respiratory devices for people with asthma and COPD [S1]. The standard company boilerplate adds that MVP is a leader in emergency pain relief and respiratory products. It lists Penthrox users as Australian hospitals including emergency departments, ambulance services, the Australian Defence Force and sports medicine, plus analgesia for short procedures such as burns dressing changes, biopsies and dental procedures [S2]. ### Independent characterisation MVP is a single-molecule specialty pharma company with a small medical-device distribution business attached. Penthrox generated 74% of FY26 revenue (A$31.6m of A$42.6m) and earned almost all segment profit (Pain Management segment EBIT A$9.4m against Respiratory A$0.7m) [S1]. The business has four structural features: 1. **Vertically integrated manufacturer of a niche, hard-to-replicate product.** Methoxyflurane is an old volatile anaesthetic. It was withdrawn from anaesthetic use at high doses in the 1970s because of renal toxicity, but at the low analgesic doses in the 3 mL Penthrox inhaler it has a long safety record in Australian pre-hospital care. MVP makes the drug product and device in-house in Victoria. The regulatory dossier (EU Decentralised Procedure, UK, Canada and others), manufacturing know-how and pharmacovigilance history act as barriers to entry, which matters because patent protection on the molecule itself is not a meaningful moat. 2. **Hybrid commercial model.** In Australia MVP sells Penthrox directly to ambulance services, hospitals and procedural/other segments (Australia was 57% of Pain Management revenue in FY26). Everywhere else it sells to exclusive in-country distribution partners at transfer prices. Partners hold the market authorisations or promotional rights and set in-market price. Since 1 May 2025 (Switzerland, Labatec) and 1 July 2025 (France, Ethypharm), the company has had no direct in-market European commercial operation [S3]. 3. **Revenue model.** Almost entirely product sales, recognised on transfer of control. A small stream of licensing and milestone income comes from upfront partner payments that are deferred and amortised over contract terms: A$0.5–0.6m recognised in FY26, A$0.2m in FY25, and A$0.85m still deferred at 30 June 2026, mainly for Thailand distribution [S1]. There is no subscription or service revenue. Approximate FY26 mix: product sales about 98.6%, amortised milestone/licence income about 1.4% (derived). 4. **Value chain position.** MVP sits in manufacturing (Penthrox) and brand-owner distribution (Respiratory devices, which rely on a small number of third-party manufacturers and suppliers [S1]). It has no reimbursement control. In Australia, PBS listing of Penthrox in the Prescriber Bag (Doctor's Bag) supports community/GP access, and a 25% PBS price increase in August 2024 was a major margin driver [S12, S3]. ### Customer types and end-markets | End-market | Customer type | Product | Notes | |---|---|---|---| | Pre-hospital emergency care | State ambulance services (Australia), NHS ambulance trusts (UK, via partner), European EMS | Penthrox | Used across all Australian ambulance services; Australian ambulance demand +4% in FY26 [S1, S12] | | Hospital emergency departments | Public and private hospitals | Penthrox | Main growth vector. Australian hospital volume +43% FY25, +28% FY26. 244 purchasing hospitals as of FY24 [S4, S3, S1] | | Procedural analgesia | Day surgery, women's health, dental, dermatology/cosmetic, burns units | Penthrox | "Other segments" demand +5% in FY26, with growth in procedural segments including women's health [S1] | | Defence, sports medicine, mining/remote first aid | Australian Defence Force, sports clubs, industrial first aid | Penthrox | Legacy Australian niches | | Community / primary care | GPs, Nurse Practitioners via PBS Prescriber Bag | Penthrox | Nurse Practitioners added to PBS Prescriber Bag eligibility in Oct 2025 [S2] | | International partners | Distributors (UK/Ireland, Nordics, France, Switzerland, Canada, Middle East, Asia, South Africa) | Penthrox | One Pain Management customer exceeded 10% of group revenue in FY26 (A$4.7m), probably a European partner (unnamed) [S1] | | Retail pharmacy / consumer respiratory | Pharmacy wholesalers, retailers, US distribution partners | Respiratory devices | US revenue A$6.1m in FY26; Australia A$3.0m [S1] |

RevenueN/A
Employees68
Market CapN/A
Founded1970
Victoria, Australia
Medialink

Medialink Group Limited

Premium
Information Technology

Medialink is a Hong Kong-based intellectual property (IP) management house. For over 30 years it has acted as a regional middleman between rights owners, mainly Japanese anime studios and committees, Chinese animation producers and Western character-brand owners, and Asian monetisation channels. Those channels include streaming platforms, broadcasters, cinemas, airlines, licensees, retailers and fans directly. It runs two reported segments. Media Content Distribution (53.2% of FY2026 revenue) sub-licenses anime series, feature films and dramas. Brand Licensing (46.8%) sub-licenses and acts as agent for roughly 500 brands, and increasingly sells its own merchandise. The group carries no bank debt and pays out about half of profits. It is layering owned channels (the Ani-One® and Ani-Mi® YouTube networks with more than 11 million combined subscriptions, Ani-Mall® e-commerce), an original IP (Linku® designer toys) and a mega-event platform (CON-CON®) on top of its traditional rights trading. The aim is to evolve from rights broker into an "IP trading hub" for Asia. --- ### Company's own description (FY2026 results announcement, FY2025 ESG Report) The company describes itself as having been "engaged in managing intellectual property rights on media content and brand licensing for over 30 years." In Media Content Distribution, it invests in and cooperates closely with media content licensors through production and distribution arrangements, and distributes animation series, variety shows, drama series, and animated and live-action feature films. In Brand Licensing, it licenses rights in brands owned by brand licensors, including merchandising rights, location-based entertainment rights and promotion rights, in the Asia Pacific region. It also acts as licensing agent for brand owners. The chairman's statements since FY2023 frame the strategic ambition as helping Hong Kong become a "regional intellectual property trading centre," in line with the PRC 14th and 15th Five-Year Plans. ### Independent characterisation Medialink is best understood as an asset-light, working-capital-intensive rights intermediary. Its core economic activity is buying time-limited, territory-limited rights from licensors, usually against minimum guarantees (MGs) paid in instalments early in the licence term, and reselling or sub-licensing those rights to many downstream buyers across Asia. Revenue recognition is predominantly point-in-time: 255.4M of 320.3M in H1 FY2026 (79.7%) was recognised at a point in time, mainly upon issue of letters of authorisation to content buyers. Only part of brand sub-licensing and agency income is recognised over time. This produces lumpy revenue around big title launches and makes period results sensitive to the timing of deliveries. The single most important economic line is cost of sales, which consists primarily of royalty payments to licensors. Gross margins have been remarkably stable at 47.9–49.7% over FY2021–FY2026. The second most important line is the recurring write-down of licensed rights to net realisable value, booked in "other expenses." It rose from HK$20.6M (FY2021) to HK$69.3M (FY2026), when it equalled 10.8% of revenue. This is effectively the cost of MG over-payment on titles that underperform. It is the key swing factor between gross profit and net profit. ### Business model and revenue model mix | Revenue line (HK$ M) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | |---|---|---|---|---|---| | Distribution of licensed media contents | 254.5 | 253.8 | 292.7 | 243.0 | 273.7 | | Distribution of feature films | 18.6 | 60.6 | 32.3 | 112.1 | 67.7 | | Sub-licensing of brands | 76.2 | 96.1 | 92.8 | 193.5 | 178.4 | | Provision of licensing agency services | 36.9 | 34.9 | 34.1 | 31.1 | 44.1 | | Sales of merchandise | 8.9 | 28.8 | 39.5 | 68.8 | 77.8 | | Fair value changes on investments in media contents | 2.7 | -0.3 | -2.5 | -0.6 | 0.0 | | Total revenue | 397.9 | 473.9 | 488.8 | 647.8 | 641.6 | *Source: Note 4 "Revenue" in annual results announcements FY2022–FY2026. The FY2026 MD&A cites merchandise revenue of HK$77.6M while Note 4 shows HK$77.8M; Note 4 is used here.* Mapped to the product / service / subscription / licensing taxonomy requested, FY2026 revenue was about 88% licensing / sub-licensing (content distribution, film distribution and brand sub-licensing), 7% agency services (commission-based) and 12% product sales (merchandise). The percentages sum to slightly over 100% because theatrical film distribution blends licensing and box-office share. Subscription income from Ani-One® YouTube memberships (Ani-One ULTRA, launched 1 July 2021) and AVOD advertising is embedded in content distribution and not separately disclosed. ### Value chain position **Upstream (suppliers / licensors):** 162 core suppliers in FY2025, located in Japan, the US, Europe, Hong Kong, Mainland China and Southeast Asia (FY2025 ESG Report). They include anime production committees, Chinese animation producers, and Western brand owners such as Sesame Workshop (Sesame Street), POMASE / Le Petit Prince, LINE FRIENDS, Garfield, Popeye, Mr. Men Little Miss, Peppa Pig, PJ Masks, Gundam, Cardcaptor Sakura and emoji®. **Midstream (Medialink):** rights acquisition, localisation (subtitling and dubbing), marketing, sub-licensing, agency, event production and merchandise design. **Downstream (customers):** global streamers (Netflix, Amazon Prime Video, Disney+, iQIYI, Bilibili, Viu, and Laftel in South Korea from FY2025), local OTT platforms (21 platforms across 8 territories for the Ani-One® OTT channel as of FY2023), cinemas in Hong Kong, Macau, Taiwan and Southeast Asia, airlines (inflight entertainment), consumer product licensees (for example GU, Coca-Cola, Kotobukiya, Pop Mart, CASETiFY and NetEase for games), shopping malls and event venues (location-based entertainment), and consumers directly via Ani-Mall®, pop-up stores and YouTube. ### Customer types and end-markets The end markets are B2B content licensing (SVOD/AVOD/TV/IPTV), theatrical exhibition, inflight entertainment, consumer products licensing (toys, apparel, F&B, health and beauty, digital collectibles, games), location-based entertainment (malls, exhibitions, concerts, conventions) and B2C merchandise. By geography, FY2026 revenue was 57.4% Asia excluding Hong Kong, 24.1% Americas and Europe, and 18.5% Hong Kong (derived from Note 4). The "Americas and Europe" bucket largely reflects the billing domicile of global platforms (for example US-headquartered streamers buying Asian rights). It does not indicate consumption in those regions.

Revenue$0.1B
Employees199
Market CapN/A
Founded1994
Kowloon, Hong Kong
McPherson's

McPherson's Limited

Premium
Information Technology

McPherson's Limited is a small-cap Australian brand owner in health and beauty. It traces its history to 1860 and is one of the oldest continuously operating companies on the ASX. After more than a decade of selling non-core businesses (printing, housewares, home appliances and, in 2024, Multix), it now focuses on five core brands. Manicare (beauty tools) and Swisspers (cotton) lead their categories in Australia, and Lady Jayne leads hair accessories. Dr. LeWinn's (anti-ageing skincare) and Fusion Health (herbal vitamins and supplements) are challenger brands in larger, faster-growing categories. Manufacturing is fully outsourced, mainly to Asia and Australia. Since FY25 the company has distributed through pharmacy wholesalers and a third-party logistics provider instead of delivering direct to stores. FY26 revenue was $118.3M and underlying EBITDA $4.3M. The company holds net cash, but faces a pending ASIC penalty and needs to show that its brands can grow under the new operating model. --- ### What the company does McPherson's markets and distributes beauty care, hair care, skin care, vitamins, supplements and personal-care items such as facial wipes, cotton pads and foot-comfort products. It operates in Australia, New Zealand and Asia (FY26 Directors' Report, Principal Activities). It does not manufacture. Production is outsourced to contract manufacturers mainly in Asia and Australia. It keeps a Hong Kong presence for sourcing and quality assurance, and a presence in the People's Republic of China for distribution and sales. **The company's own description (FY26 Annual Report, paraphrased):** McPherson's describes itself as a leading supplier of health and beauty products. Most of its revenue comes from five core owned brands that lead their markets (Manicare, Dr. LeWinn's, Swisspers, Lady Jayne and Fusion Health), supported by portfolio brands including Maseur, Revitanail and Bondi fragrances. In the "Likely developments" section of the FY26 Directors' Report, it calls itself a "pure-play health and beauty company" focused on growing its brands. **Strategy framework (FY26 Investor Presentation, slide 9):** **Purpose:** "Making Confidence Simple." **Vision:** to be Australia's leader in premium health and beauty products in every household, every day. **Where it plays:** - Leadership positions in established categories: beauty tools, hair accessories, cotton and foot care. - Challenger positions in larger, faster-growing categories: beauty transformation, facial skincare and vitamins, minerals and supplements (VMS). ### Business and revenue model | Dimension | Characterisation (FY26) | |---|---| | Product / service / subscription / licensing mix | About 100% branded physical products. There is no subscription or licensing revenue. A small, now-shrinking agency and distribution activity remains: an exclusive distribution agreement for Chemist Warehouse-owned brands outside the Chemist Warehouse network (from July 2022), and historically third-party agency brands that were mostly exited in FY24. | | Owned vs portfolio | Core brands were 93.4% of FY26 revenue, up from 89.7% in FY25 (FY26 Presentation, slide 15). | | Value chain position | Asset-light brand owner and marketer covering brand management, product development, sourcing and quality assurance, sales and A&P. Manufacturing, warehousing (third-party logistics provider from FY25) and much of pharmacy delivery (wholesalers) are outsourced. | | Customer types | Major pharmacy chains, including Chemist Warehouse, the largest customer and a strategic-alliance partner since 2022; independent pharmacies, now served mainly through wholesalers (Symbion, API and at least one other large wholesaler); grocery (supermarket majors); specialty beauty; health food stores (important for Fusion Health); e-commerce marketplaces (Amazon); its own direct-to-consumer sites (Dr. LeWinn's and Fusion Health, launched in FY26); and international distributors, mainly China for Dr. LeWinn's. | | End markets | Australian and New Zealand consumer health and beauty: beauty accessories, cotton, hair accessories, foot care, facial skincare and VMS. International sales were $2.6M in FY26, about 2.2% of revenue. | | Key non-IFRS metric | CAAP (contribution after advertising and promotion) = gross margin less distribution costs and A&P. FY26 CAAP was $41.6M, a 35.2% margin. | ### Independent characterisation McPherson's is a sub-scale owner of consumer brands whose earnings depend heavily on a few Australian pharmacy and grocery buyers. Its three category leaders (Manicare, Swisspers and Lady Jayne) are, in effect, private-label-adjacent accessory brands. They have high shelf share but low pricing power, and they face competition from retailer house brands. The two growth brands, Dr. LeWinn's and Fusion Health, hold small shares (2.3% and 0.6% of their pharmacy categories) in large categories where multinationals dominate. Divestments and the move to wholesalers have made the business simpler, but they also removed scale. Fixed costs fell faster than revenue only partly, and FY26 underlying EBITDA margin was 3.6%. The balance sheet is clean (net cash, undrawn facilities), and the shares trade below net tangible assets. The investment case now rests almost entirely on whether the company can restore revenue growth in FY27 on a lower fixed-cost base.

Revenue$0.1B
Employees22
Market CapN/A
Founded1860
where the lease expires on June, Australia
McMillan

McMillan Shakespeare Limited

Premium
Information Technology

McMillan Shakespeare is Australia's longest-established listed provider of employee-benefit administration. Its two core activities are salary packaging and novated leasing. It also has a specialist fleet-management arm and the country's second-largest NDIS plan-management business. It serves about 550,000 customers through nine brands: Maxxia, RemServ, Oly, Onboard Finance, Interleasing, Just Honk, Plan Partners, Plan Tracker and My Plan Support. These customers come largely through long-dated employer contracts with public-sector, health, charity and corporate clients. The model is capital-light at the administration layer and earns a ROCE of 62.1% (FY26). Recurring per-member fees are layered with transaction-linked novated commissions and a growing in-house funding warehouse (Onboard Finance, $587m in receivables). MMS's earnings are tied to Australian tax policy, especially FBT and the Electric Car Discount, and to NDIS settings. That gives it policy-driven tailwinds and concentrated regulatory risk. In FY26 it delivered record UNPATA of $107.9m and a 41.5% operating margin, and pays 70–100% of UNPATA as fully franked dividends. --- ### Company's own description (AR FY26) MMS describes itself as "a provider of salary packaging, novated leasing, disability plan management, support coordination, asset management and related financial products and services." It states that it manages programs for "some of the largest public sector, corporate and charitable organisations." Its purpose is "to make a difference to people's lives", and its vision is to be "the trusted partner, providing solutions in making matters simple." It operates three segments: - Group Remuneration Services (GRS) - Asset Management Services (AMS) - Plan and Support Services (PSS) ### Independent characterisation MMS is best understood as a tax-and-benefits administration platform with three distinct economic engines. **1. Salary packaging administration (GRS)** - Employers, especially public hospitals, health services, government departments and charities with FBT concessions, outsource salary-packaging administration to MMS. - MMS earns recurring per-package fees, largely paid by employees. - It also earns interest on restricted client trust funds ($470.2m at 30 Jun 2026) and ancillary product income. - This is an annuity-style, contract-based business with high switching costs. Tender cycles for large public-sector clients typically run multiple years (exact terms not publicly disclosed). **2. Novated leasing origination and funding (GRS)** - Employees salary-sacrifice vehicle costs under a three-party novated lease. - MMS earns upfront commissions from third-party financiers and insurers, plus ongoing administration fees. - Since FY2023 it has increasingly funded leases itself through Onboard Finance (OBF). OBF receivables were $587m at 30 Jun 2026 (+16.6%). This turns commission income into a multi-year net-interest-margin stream. - This leg is cyclical and heavily policy-sensitive: FBT, the Electric Car Discount and vehicle supply all matter. **3. Fleet leasing and management (AMS)** - Through Interleasing (Australia and NZ), MMS funds, manages and remarkets operating- and finance-leased commercial fleets. It had about 16,000 units and a written-down value of $382.3m (FY26). - Just Honk is a used-car retail outlet for end-of-lease disposals. - AMS is balance-sheet intensive and exposed to residual-value and used-vehicle price risk. **4. NDIS plan management and support coordination (PSS)** - Under Plan Partners, Plan Tracker and My Plan Support, MMS pays providers' invoices on behalf of about 44,000 NDIS participants. - It earns regulated monthly fees set by the NDIA price guide. - This is a fee-for-service business whose pricing and market structure are set entirely by government. ### Revenue-model mix | Revenue type | Where earned | Character | |---|---|---| | Recurring administration fees (per package / per lease / per participant) | GRS, PSS, AMS management fees | Subscription-like, contracted | | Transactional commissions (finance, insurance and product origination on novated leases) | GRS | Volume-linked, policy-sensitive | | Net interest / lease income (OBF finance-lease receivables; AMS operating and finance leases) | GRS (OBF), AMS | Balance-sheet, annuity over lease term | | Interest on client trust funds | GRS / Group | Rate-sensitive | | Remarketing / end-of-contract vehicle sales | AMS (incl. Just Honk) | Cyclical, residual-value dependent | A precise split by revenue type is not publicly disclosed in the sources reviewed. Statutory revenue of $602.1m (FY26) comprises $581.1m of "revenue" and $21.0m of "interest revenue" (AR FY26). ### Value-chain position, customers and end-markets **Value-chain position** - MMS sits between employers (who grant access to their workforce), employees (the end customers), OEMs and dealers (vehicle supply), and third-party financiers and insurers (product manufacturers). - Through OBF and AMS it is increasingly also the financier. - In PSS it sits between the NDIA (payer), participants and disability service providers. **Customer types** - Clients: employers, government agencies and corporates (fleet). - Consumers: employees, NDIS participants and SME employees via Oly. **End-markets** - Australian public health and hospital sector - Federal, state and local government - Not-for-profit and charitable (PBI) sector - Corporate employers and SMEs - Commercial fleets (Australia and NZ) - The National Disability Insurance Scheme

Revenue$0.4B
Employees1,263
Market CapN/A
Founded1988
Melbourne, Australia
MCMining

MC Mining Ltd

Premium
Information Technology

MC Mining is a small-cap South African coal company that has spent most of its history as a developer. It is now crossing into commercial production at its flagship Makhado steelmaking hard coking coal (HCC) mine in Limpopo Province. The foundation phase of Makhado is designed to produce about 800,000 tonnes a year of a mid-volatile HCC product (HCC 64 Mid Vol) plus a 5,500 kcal thermal coal by-product. It has a planned 28-year life of mine. Management describes it as set to become South Africa's largest HCC producer, initially selling into the domestic steel industry. The legacy cash-generating asset, the Uitkomst Colliery in KwaZulu-Natal, was placed on care and maintenance in March 2026, and a binding offer for it is being considered. Since April 2026 the company has been majority-owned (51%) by Hong Kong-listed Kinetic Development Group, a Chinese coal producer that funds its development. The investment case therefore turns on Makhado's ramp-up, KDG's continued financial support and coking coal prices. --- ### What the company does MC Mining explores for, develops and mines coal in South Africa. Its business has four asset pillars: 1. **Makhado Project** (67% attributable once the black economic empowerment transaction completes). Steelmaking HCC with a thermal coal by-product, in the Soutpansberg Coalfield, Limpopo. Plant commissioning took place May–August 2026, with ramp-up targeted in the September 2026 quarter. 2. **Uitkomst Colliery** (84%). An underground metallurgical and thermal coal mine in the Utrecht Coalfield, KwaZulu-Natal. Historically the only revenue source; mining and processing were suspended effective 1 March 2026. 3. **Vele Aluwani Colliery** (100%). Semi-soft coking coal (SSCC) and thermal coal in the Tuli Coalfield, Limpopo. Suspended, pending a re-engineered business plan and a viable logistics solution. 4. **Greater Soutpansberg Projects (GSP)** (mostly 74%, some farms 100%). Includes the Chapudi, Generaal and Mopane project areas. These are mining-right tenements next to Makhado. Management describes the GSP as the long-term greenfield growth platform with over 7.0 billion tonnes of coal in place (FY2025 H1 interim report). That figure is a gross in-situ characterisation and not a JORC/SAMREC reserve. The company also holds small legacy Australian royalty interests: Kanowna West & Kalbara, Abbotshall, and Kookynie gold tenements, with 0.5% net smelter royalties, plus a 5.99% interest in one tenement (M27/181). These are immaterial. ### Company's own description In its 2026 quarterly reports, MC Mining describes itself as an ASX/JSE-listed coal exploration, development and mining company operating in South Africa. It lists its key projects as Uitkomst (metallurgical and thermal coal), Makhado (hard coking coal), Vele (semi-soft coking and thermal coal) and the GSP (coking and thermal coal). Its May 2026 announcement completing the KDG subscription says it intends to become a meaningful new entrant in the global seaborne metallurgical coal market. It also notes a capacity expansion programme under design and testing that targets 800,000 t/y of HCC and 700,000 t/y of thermal coal in total. ### Business model and revenue model | Dimension | Characterisation | |---|---| | Revenue model | 100% product sales (physical coal). No service, subscription or licensing revenue. Legacy Australian royalties are immaterial and not separately disclosed. | | Value chain position | Upstream: mining, beneficiation (washing in a coal handling and preparation plant, CHPP), and road logistics to customers or port. Mining is outsourced to contractors (JCI Mining at Makhado). Plant construction is contracted (Enprotec). | | Customer types | Uitkomst (historical): domestic metallurgical and industrial buyers (premium duff, sized peas) and lower-grade middlings buyers. A marketing arrangement with a trader, Paladar, ran on a trial basis until its expiry in July 2024 and was not extended. Makhado: domestic steelmakers initially, with seaborne export optionality. Weighbridges were commissioned and trial runs to port were being prepared in August 2026. | | End markets | Steelmaking (coking coal); industrial and energy (thermal coal, including the API4-referenced 5,500 kcal product) | | Pricing | Linked to international benchmarks (premium HCC; API4 Richards Bay thermal). The company reports average benchmark prices each quarter. Specific contract terms are not publicly disclosed. | ### Independent characterisation MC Mining is effectively a single-asset development company in transition to production. Its parent is a strategic Chinese coal investor. Historically it was a serial underachiever. As Coal of Africa, it accumulated about US$988M of retained losses by December 2025 (S&P balance sheet data) across failed or stalled projects (Mooiplaats, Vele) and costly legacy contracts. The KDG recapitalisation solved Makhado's financing gap, which had lasted for years. In return, minority shareholders now hold a stock controlled by one funder. Liquidity is fragile: the company had US$2.9M of cash and US$54.4M of current liabilities at 30 June 2026, and its auditors flagged material uncertainty on going concern. Operating revenue is now near zero until Makhado ships coal.

Revenue$0.0B
Employees650
Market CapN/A
Founded1979
United States, North America
MaynePharma

Mayne Pharma Group Limited

Premium
Information Technology

Mayne Pharma is a small-cap specialty pharmaceutical company. It is listed in Australia, but its economic centre of gravity is the United States, where roughly 82% of revenue is generated. Since FY22 it has been rebuilt from a debt-laden generics and contract-manufacturing conglomerate into a branded US women's-health and dermatology franchise. It is anchored by four women's-health brands: - NEXTSTELLIS®, an estetrol-based oral contraceptive - ANNOVERA®, a one-year vaginal ring - IMVEXXY®, a vaginal estradiol insert - BIJUVA®, an estradiol/progesterone capsule These sit alongside a margin-focused dermatology portfolio and an Australian manufacturing and export arm at Salisbury. Its newest strategic asset is DistributeRx. Launched in March 2026, it is a direct-to-patient, cash-pay prescription channel built on its Adelaide Apothecary mail-order pharmacy, and it is now open to third-party manufacturers. FY26 revenue was A$383.7m at a 64.7% gross margin, with underlying EBITDA of A$34.2m. The company holds A$80.0m of cash against A$43.2m of interest-bearing debt. Large contingent earn-out liabilities (A$265.5m) linked to acquired brands are the main balance-sheet overhang. --- ### Company's own description (FY26 Annual Report, paraphrased) The company describes itself as an ASX-listed specialty pharmaceutical company that commercialises novel branded women's-health and dermatology medicines. Its stated aim is to offer patients better, safe and more accessible medicines. It points to: - A 40-year record in oral drug-delivery technologies. - A Salisbury (South Australia) development and manufacturing facility with expertise in complex oral and topical dose forms, including modified-release products and poorly soluble compounds. - A contract development and manufacturing (CDMO) service for third parties. ### Independent characterisation Mayne Pharma is best understood as a US commercial-stage, in-licensing and acquisition-led branded pharma platform. It has an Australian manufacturing tail. It does not carry out early-stage drug discovery. Its model has three parts: 1. **Acquiring or licensing** late-stage or already-approved US brands. Consideration is often heavily deferred through earn-outs and royalties. 2. **Re-launching those brands** through a focused US sales force of OB/GYN and dermatology representatives, supported by medical science liaisons. 3. **Managing gross-to-net economics** through channel strategy: specialty pharmacies, its own Adelaide Apothecary mail-order pharmacy, GoodRx-enabled cash prices, and now DistributeRx. The Australian business manufactures and sells branded and generic products ex-US and provides CDMO services. ### Revenue model mix | Revenue line (A$m) | FY2024 | FY2025 | FY2026 | |---|---|---|---| | Sale of goods | 351.8 | 364.2 | 352.3 | | Services revenue | 35.3 | 42.4 | 26.0 | | Licence fee revenue | 0.2 | 0.4 | 0.0 | | Royalties revenue | 1.1 | 1.2 | 5.3 | | Total revenue | 388.4 | 408.1 | 383.7 | *Source: FY25 and FY26 Annual Reports, consolidated statement of profit or loss.* **Mix in FY26:** - Products: 91.8% of revenue. - Services: 6.8%, mainly distribution, pharmacy and contract-manufacturing related. - Royalties: 1.4%. - There is no subscription revenue. - Branded products were 83% of net sales in FY26, up from 79% in FY25. Generics were 17% (FY26 Annual Report). ### Value-chain position | Value-chain stage | Mayne role | |---|---| | Discovery / early R&D | Minimal. R&D expense is mainly post-marketing studies and lifecycle work (A$20.7m in FY26) | | Late-stage development / regulatory | Selective: post-approval FDA studies for ANNOVERA® and IMVEXXY®; formulation work at Salisbury | | Manufacturing | US brands are largely third-party manufactured. Salisbury makes Australian and export products and CDMO volumes | | Commercialisation | Core competency: US field force and marketing for women's health; digital and channel-led dermatology | | Distribution / dispensing | Increasingly vertical: Adelaide Apothecary (licensed US mail-order pharmacy) and DistributeRx (direct-to-patient platform) | ### Customers and end-markets **Ultimate prescribers:** - US OB/GYNs, women's-health nurse practitioners and primary care physicians. - US dermatologists, with 5,042 unique prescribers using DistributeRx since its March 2026 launch. - Australian GPs and specialists. **Paying and purchasing customers:** - US wholesalers and specialty pharmacies (more than 400 in the dermatology channel network). - PBMs and payers, through rebates. - Patients paying cash through Adelaide Apothecary and DistributeRx. - Australian pharmacy wholesalers, with PBS reimbursement. - Export distributors, for example KADIAN® in Canada. - CDMO clients. **End-markets:** - US contraception - US menopause and hormone therapy - US medical dermatology (acne, rosacea, psoriasis) - Australian prescription pharmaceuticals, including pain (opioids) and urology - Contract manufacturing

RevenueN/A
Employees470
Market CapN/A
Founded2005
Salisbury South, Australia
Mayfield

Mayfield Group Investments Pty Ltd

Premium
Information Technology

| Field | Detail | Source | |---|---|---| | Legal name | Mayfield Group Holdings Limited | FY2026 ASX Release, 27 Aug 2026 | | ABN | 57 010 597 672 | FY2026 ASX Release | | Former names | Stream Group Limited (ASX: SGO; name change effective c. 20 Nov 2020); Longreach Group Limited (ASX: LRG; until c. 31 Jan 2014); Allied Technologies Group Limited (ASX: ATZ; until c. 15 Feb 2007) | Market Index former-name register | | Founding year | Operating business (Mayfield Industries): management buy-out in 2012; Google Finance lists "founded 1936" for the operating lineage | MarketIndex director profile of A. Steele; Google Finance | | Incorporation jurisdiction | Australia | ASX listing | | Headquarters | 3 Gidgie Court, Edinburgh, South Australia 5111 | FY2026 ASX Release | | Exchange / ticker | Australian Securities Exchange: MYG | ASX | | Index membership | S&P/ASX All Ordinaries, added effective 23 Mar 2026 (announced 10 Mar 2026) | S&P DJI rebalance notice via InvestSMART | | ISIN | AU0000119331 | Parqet | | CUSIP | Not applicable (no US listing) | — | | WKN (Germany) | A2QJL9 | Parqet | | Fiscal year end | 30 June | Annual reports | | Employees | 535 at 30 Jun 2026; earlier data points c. 200 (Sep 2021) and 215 (Morningstar profile, undated) | FY2026 Investor Presentation; InDaily, Sep 2021; Morningstar | | Auditor | — | — | | Share registry | Automic Group | Market Index | | Shares on issue | c. 119.2M (implied by the A$2.86M estimated final dividend at 2.4 cps, based on shares on issue at 31 Jul 2026) | FY2026 Investor Presentation, slide 24 | | Market capitalisation | c. A$257M at A$2.16 (close on 6 Aug 2026, the last verified quote) × 119.2M shares. The stock rose about 18% on the FY2026 result day (27 Aug 2026) | FNArena; Motley Fool, 27 Aug 2026 | | Website | www.mayfieldgroup.com.au; investor hub at investors.mayfieldgroup.com.au | FY2026 ASX Release | | Managing Director & CEO | Andrew Rowe (since 3 Oct 2023) | Simply Wall St; InvestSMART | | Chair | Simon Higgins, Non-Executive Chair (since 14 Feb 2022) | InvestSMART; MarketScreener | Mayfield Group Holdings is a South Australian electrical infrastructure manufacturer. It designs, builds and services the switchboards, transportable switchrooms, kiosk substations, protection panels and control rooms that connect power to Australia's data centres, mines, renewable energy zones, utilities, defence sites and transport infrastructure. Its earnings engine is factory-based, project-driven manufacturing. Plants are located in Adelaide, Perth and Kalgoorlie, with service operations in every mainland state capital. This core is supplemented by two smaller platforms. Critical Control & Communications (ATI Australia) provides telecommunications and remote-control networks. Product Solutions (Power Parameters) supplies UPS systems, batteries and test instruments. In FY2026 revenue grew 43% to A$169.0M and underlying EBITDA rose 54% to A$18.5M. These results reflect strong data-centre and mining demand, plus three bolt-on acquisitions in twelve months: BE Switchcraft, SMEC Power & Technology and the Nilsen switchboards division. Management describes Mayfield as the only ASX-listed pure-play electrical infrastructure manufacturer. Its investment case rests on the view that sovereign, onshore manufacturing capacity is a strategic asset in Australia's electrification cycle. --- ### What the company does Mayfield designs, manufactures, installs, commissions and maintains low- and medium-voltage electrical distribution infrastructure, together with associated communications and critical-power products. The FY2026 Investor Presentation describes the group as one reportable operating segment, presented through three operating "platforms" for context: 1. **Manufacturing.** This is the primary earnings driver. It covers Australian-made switchboards, transportable switchrooms, kiosk substations and custom project solutions, all manufactured in South Australia and Western Australia. It includes Mayfield Industries, BE Switchcraft (acquired Aug 2025), SMEC Power & Technology (acquired Mar 2026) and, from FY2027, the N-Series switchboard platform acquired from Nilsen. 2. **Critical Control & Communications.** This platform is project-based. It provides communications and network solutions that let customers monitor and control remote sites, built on ATI Australia's telecommunications capability (ATI became 100% owned in Sep 2021). 3. **Product Solutions.** This platform supplies critical-power components: UPS systems, batteries, battery testers, cable fault tracers and test instruments. It is delivered mainly through Power Parameters (headquartered in Broadmeadows, Victoria). A services capability supports all three platforms. Mayfield Services (formerly STE Solutions Pty Ltd, renamed in FY2022) is positioned as the service and maintenance provider for Mayfield Industries' installed products (FY2022 Annual Report). ### Company's own description (paraphrased from the FY2026 ASX Release) Mayfield describes itself as the designer, manufacturer and service provider for the critical electrical infrastructure behind Australia's energy transition, data-centre build-out, defence modernisation, mining operations and national infrastructure. Its stated thesis is that new technologies such as solar farms, data centres, EVs and AI computing all depend on reliable power distribution, and that Mayfield supplies that foundational layer. It highlights onshore manufacturing as a supply-chain-security advantage. Its customer base comprises major contractors, utilities, miners, infrastructure operators and government. ### Revenue model | Revenue type | Description | Indicative share | Source / note | |---|---|---|---| | Manufactured products (project-based) | Engineered-to-order switchrooms, switchboards, kiosk substations and protection panels, recognised over time against contract milestones (contract assets of A$13.7M at 30 Jun 2026) | Majority of revenue; exact % not disclosed | Morningstar profile states the majority of revenue comes from sale of manufactured products | | Short-cycle manufactured products | Commercial and light-industrial switchboards (BE Switchcraft, N-Series); mining electrical equipment (SMEC) | Not disclosed | FY2026 Investor Presentation describes these as short-cycle businesses | | Traded and distributed products | UPS, batteries, test instruments (Power Parameters) | Not disclosed; described as stable | FY2026 ASX Release | | Communications projects and services | Network design, build and integration (ATI Australia) | Not disclosed | FY2026 Investor Presentation | | Maintenance and lifecycle services | Service, maintenance, modernisation, replacement | Not disclosed | FY2026 Investor Presentation, slide 22 | | Subscription / licensing | None disclosed | 0 | — | ### Value-chain position Mayfield sits in the midstream fabrication and integration layer. It buys components such as circuit breakers, busbar, enclosures, protection relays, transformers and cable, much of it from global OEMs. It then engineers and assembles them into application-specific, factory-tested assemblies that are delivered to EPC contractors or directly to asset owners. The product range spans the full lifecycle of design, install, service and maintain, modernise, and replace (FY2026 Investor Presentation, slide 22). Value-add comes from engineering design, compliance and type-testing, factory integration, logistics of transportable modules, and site commissioning. ### Customer types and end markets The FY2026 Investor Presentation lists ten key industries served: Telecommunications; Defence; Industrial & Commercial; Data Centres; Renewable Energy; Mining & Resources; Utilities & Networks; and Infrastructure & Transport. It also identifies four structural demand themes: **AI and data centres:** Now described as one of the largest sources of activity and pipeline. **Mining electrification:** SMEC reportedly services 85% of the top 20 WA gold producers. **Energy transition:** Renewables, BESS and kiosk substations. **Critical infrastructure:** Utilities, transport, defence and telecommunications. ### Independent characterisation Mayfield is best understood as a small-cap, capacity-constrained, engineered-to-order electrical fabricator that is transitioning into a multi-site, multi-brand roll-up. Its earnings quality depends on three things: 1. Factory throughput, measured in square metres of production space and skilled labour. 2. Project pricing and commercial discipline. The FY2022 loss in the services arm shows how one bad contract can swing group profit. 3. Working-capital management on milestone-billed contracts. The FY2026 acquisitions deliberately add short-cycle revenue (commercial switchboards and mining products). This dampens the lumpiness of large switchroom projects.

Revenue$0.1B
Employees535
Market CapN/A
Founded1980
Edinburgh, Australia
Mayfield

Mayfield Childcare Limited

Premium
Information Technology

Mayfield Childcare is a sub-scale, ASX-listed operator of long day care (LDC) centres. It runs 45 leased centres with about 4,195 licensed places across Victoria, Queensland and South Australia, and is heavily concentrated in Melbourne and regional Victoria. Mayfield was built through acquisition. It listed in 2016 as a roll-up of 16 family-run centres and grew sharply through the 2021 purchase of 14 Genius Learning centres and the 2024 rescue acquisition of the Adelaide Montessori operator Precious Cargo. Since 2023 it has been in near-continuous repair mode. That period has included: - a forensic investigation into the founder era; - three CEO regimes; - board contests and a Takeovers Panel application; - two years of goodwill impairments totalling about A$30 million; - an unsolicited takeover that left rival Embark Early Education with about 49.8% of the register. Occupancy in the low-to-mid 50s%, a sector-wide oversupply and wage inflation under subsidy-linked fee constraints have pushed underlying group EBITDA to a loss in HY26. Management's turnaround rests on centre-level accountability, portfolio pruning, about A$2.6 million of annualised structural savings, and the nascent Mayfield 360 allied-health platform. --- ### Company's own description (AR25, paraphrased) Mayfield describes its principal activity as operating long day childcare centres in Victoria, Queensland and South Australia. It frames its purpose around delivering high-quality education and care that meets or exceeds the National Quality Standard (NQS). The brand idea is a "home away from home" grounded in each local community. The company describes a centralised, cost-effective management structure designed to simplify operations and the integration of acquired centres. It states a growth intent of buying established centres that meet criteria on supply/demand metrics, size, location, utilisation and profitability. AR25 also sets out five organisational values: - child-first always; - community and compassion; - excellence in care and learning; - integrity and accountability; - innovation with purpose. The company reports one operating segment (long day care services provider) and one geographic segment (Australia). It has no major customers, because revenue is earned from individual families (AR25, Note 4). ### Business model and revenue model | Revenue component | Nature | FY2025 (A$M) | FY2024 (A$M) | Source | |---|---|---|---|---| | Childcare services (fees + CCS) | Service, recurring weekly billing | 91.412 | 87.156 | AR25 Note 5 | | Other income (insurance, other) | Non-recurring / other | 0.140 | 1.152 | AR25 Note 5 (FY24 included 0.656 of business-interruption insurance) | | Mayfield 360 allied health | Fee-for-service, NDIS-registered | Pre-revenue (pilot) | – | AGM26; HY26 | | Subscription / licensing | None | 0 | 0 | – | Mayfield is a pure service business. It sells session-based care: daily fees, billed weekly and generally paid within a week (AR25, Note 1(d)). Revenue comes from two payers: 1. **Families**, who pay the "gap" fee net of subsidy. 2. **The Commonwealth Government**, through the Child Care Subsidy (CCS), paid to the provider on the family's behalf. Smaller revenue lines include: - State kindergarten funding, such as Victorian funded kinder programs delivered inside LDC centres; - Inclusion Support funding and other grants; - Non-material enrolment and wait-list fees. From 2026, a nascent fee-for-service allied-health line sits within Mayfield 360. It is billed to families and NDIS participants. ### Value-chain position Mayfield is a leasehold operator. It does not own its centre real estate. It leases buildings from a mix of single-property owners and institutional landlords: - weighted average lease term of 11.3 years; - almost half of leases carry fixed annual increases (AR25 risk section). This places Mayfield at the operating-risk end of the childcare value chain. Landlords, including listed childcare REITs, capture a fixed rent stream. Mayfield bears occupancy, labour and regulatory risk. Rent and outgoings (pre-AASB 16) were A$16.1 million in FY2025, or 17.6% of revenue (derived from AR25). Labour is the dominant cost. Centre labour was A$57.2 million in FY2025, a wage-to-revenue ratio of 62.5% (derived). The HY26 ratio was 61.5%. ### Customers and end-markets | Dimension | Detail | |---|---| | End-user | Children aged about 6 weeks to school age (0–5 years) | | Paying customers | Families (gap fee) and the Australian Government (CCS) | | Secondary payers | State governments (funded kindergarten), Inclusion Support Programme, NDIS (Mayfield 360) | | Geography | Victoria (29 centres), Queensland (8), South Australia (8) | | Mix of urban vs regional | A historically regional and metro-fringe Victorian focus, according to The Sector (2021) | | Customer concentration | None (AR25) | ### Independent characterisation Mayfield is best understood as a high-operating-leverage, low-occupancy roll-up in a subsidy-dependent, oversupplied market. Its economics turn on four variables. **(i) Occupancy.** Group occupancy fell from 61% in FY2024 to 54% in FY2025 and to a 51.3% average in HY26 (AR25; HY26). Break-even in LDC typically requires well above these levels. **(ii) Wage-to-revenue.** This was 62–64% across FY2025–HY26. It is structurally pressured by award increases, and the government-funded Worker Retention Payment ties wage uplifts to fee-growth restrictions. **(iii) Fixed rent.** Leases are long-dated and escalating, so rent is effectively a debt-like fixed charge. Lease liabilities were A$155.5 million at FY2025 against equity of A$48.4 million. **(iv) Corporate overhead.** Head office cost was A$7.3 million in FY2025, about 8% of revenue, which is heavy for a 45-centre network. The business generates positive operating cash flow, at A$10.3 million in FY2025. However, after the principal portion of lease payments (A$8.7 million) and capex (A$1.5 million), free cash flow is near zero. This explains the equity raises in January 2025 (about A$4.3 million) and August 2026 (A$3.0 million).

RevenueN/A
Employees1,100
Market CapN/A
Founded2015
Hawthorn, Australia
Maxnerva

Maxnerva Technology Services Limited

Premium
Information Technology

Maxnerva is a small-cap, Hong Kong-listed IT solutions and services company that functions as the externally listed digital-transformation arm of the Foxconn (Hon Hai) ecosystem. Its core Digital Industry business designs and implements smart-manufacturing solutions for factories and industrial parks: ERP/MES/WMS/PLM systems, automation and robotics integration, facility energy monitoring, security and workforce systems, and testing and inspection services. Since 2025 this has extended to AI data-centre projects, notably a 100MW NVIDIA GB300 facility in Taiwan. Its secondary Digital Life business sells digital-signage solutions in Taiwan and distributes InFocus-branded smart-office equipment (projectors, conferencing peripherals) internationally as brand licensee. Roughly half of revenue comes from Hon Hai group companies, which gives Maxnerva privileged access to Foxconn's global capacity build-out in Vietnam, India, the US and Taiwan, but also means heavy related-party dependence. Hon Hai is now moving to take direct control through a pending mandatory offer. --- ### Company's own description (paraphrased from Annual Report 2025 and FY2025/H1 2026 results) Maxnerva describes itself as principally engaged in two businesses: Digital Industry and Digital Life. Its Annual Report 2025 is themed around "Digital Industry" and "Digital Life", "Powered by AI, Robots & Compute Power". In Digital Industry, the company provides a full range of smart-manufacturing solutions and services covering four areas: 1. Implementing software systems (ERP, MES, WMS and similar) together with automation equipment and robots in production lines, to cut costs and raise efficiency. 2. Implementing facility monitoring and control systems that track water, power and gas usage at production plants. 3. Implementing facial-recognition systems for labour and security management across industrial parks. 4. Providing testing and inspection services for new and existing electronic products. It also supplies the IT products, daily operating services and post-installation maintenance for these solutions. In Digital Life, it provides digital retail signage and other solutions, and sources and distributes branded smart-office equipment. The statutory description of principal activities is: sales of IT products and software applications, and provision of system integration, IT solutions development and implementation, and related maintenance services to corporate customers. (Source: FY2025 Annual Results, note 1, 25 Mar 2026.) ### Business model and revenue model | Revenue stream (RMB M) | FY2023 | FY2024 | FY2025 | H1 2025 | H1 2026 | |---|---|---|---|---|---| | IT projects – point in time | 191.4 | 211.8 | 258.5 | 185.3 | 185.6 | | IT projects – over time | 123.5 | 119.7 | 143.9 | 38.1 | 27.4 | | Maintenance & consulting – over time | 109.7 | 51.3 | 21.0 | 5.9 | 18.8 | | Sales of goods – point in time | 250.3 | 173.8 | 283.7 | 112.7 | 104.4 | | Finance + operating lease income | 3.0 | 2.4 | 0.6 | 0.2 | 0.1 | | Total | 677.9 | 558.9 | 707.6 | 342.1 | 336.3 | Revenue is recognised across five streams. The FY2025 mix shows a business that sits between product resale and project services. Sources: FY2023, FY2025 annual results; H1 2026 interim results. **Mix by type (FY2025, calc.):** - Project/solution revenue (IT projects): about 57%. - Hardware/goods sales: about 40%, mostly Digital Life smart-office equipment. - Recurring maintenance/consulting: about 3%, down sharply from 16% in FY2023. - Lease income: about 0.1%. There is no meaningful subscription or licensing revenue today. The Personify video-conferencing subscription/licensing line contracted to about US$1 million in 2023 and its IP was impaired. The decline in maintenance and consulting revenue (RMB109.7M in FY2023 to RMB21.0M in FY2025) is a notable quality-of-earnings change. It reduces the recurring revenue base and suggests either a reclassification of Hon Hai service work or the loss of IT-services scope. The filings do not explain it. ### Value-chain position Maxnerva is a solutions integrator and channel/brand operator, not a technology originator. - In Digital Industry, it sits between technology vendors (SAP, Siemens, Dell, UiPath, TeamViewer, robot makers such as UBTech) and manufacturing end-users, the largest being Hon Hai. It captures design, integration, procurement mark-up and service margins. - In Digital Life, it acts as brand licensee, supply-chain manager and distributor for InFocus-branded equipment, and as a solution provider for signage. R&D expense fell to RMB0.9M in FY2025 (0.1% of revenue), which confirms the asset-light, integration-led model. ### Customer types and end-markets | Dimension | Detail (source) | |---|---| | Related party | Hon Hai group: 50% of FY2025 revenue (RMB352.2M); 43% in FY2024; 49% in FY2023; 40% in FY2022; 47% in FY2021 | | Customer concentration | Top-5 customers 29% of revenue in FY2025 (27% FY2024; 37% FY2023; 40% FY2022; 44% FY2021). No single customer above 10% in FY2024–25. In FY2023 a single customer was 14%. | | Industrial end-markets | Electronics/3C manufacturing (core), EV (first project mid-2022: SAP for a US EV plant), semiconductor packaging and testing, appliances/water purifiers, printers, AI data centres (from 2025) | | Retail/public end-markets | Taiwan supermarket chain (400+ stores), Taoyuan International Airport, Taipei department store (via advertising media agencies) | | Office end-markets | B2B/education AV channel buyers of projectors and conferencing equipment across Europe, SE Asia (incl. Indonesia), Americas and developing markets | ### Independent characterisation Maxnerva is best understood as a captive-plus integrator. The Digital Industry engine depends on Hon Hai's global capital expenditure cycle. It benefits when Foxconn builds plants outside China (Vietnam, India, US, Mexico) or AI-server and data-centre capacity, and suffers when Foxconn and its peers cut capex, as in 2023–24. The Digital Life business is structurally weaker and lower-margin. It is exposed to consumer and SME sentiment, component costs (2026 memory price surge) and tariffs. Reported earnings have been distorted for three years by fair-value swings on two venture investments (SigmaSense, GRC Fund) and by IP impairments. The underlying operating business, measured by segment results, has been profitable every year from FY2021 to H1 2026 except Digital Life in FY2023.

Revenue$0.1B
Employees246
Market CapN/A
Founded1979
Hamilton HM, Bermuda
MaxiPARTS

MaxiPARTS Limited

Premium
Information Technology

MaxiPARTS Limited is a pure-play Australian distributor of commercial vehicle parts and workshop consumables. It was created in 2021 when the former MaxiTRANS Industries sold its volatile trailer manufacturing business and kept its parts division. The group runs two segments. MaxiPARTS Operations is a national network of about 30 branches plus embedded on-site operations, selling truck and trailer parts at wholesale and trade level. Förch Australia is the exclusive Australian distributor of German FÖRCH workshop consumables. In FY26 the group earned A$274.4m in revenue and A$28.8m in EBITDA (10.5% margin), and it ended the year in a net cash position. Since separation it has completed four acquisitions: Truckzone, Förch Australia, Independant Parts and Förch Brisbane, with Air Brake Systems pending. It has lifted EBITDA margins from mid-single digits to over 10%. Its strategic identity is that of a capital-light, cash-generative consolidator in a fragmented, non-discretionary aftermarket. Its exposure to the freight cycle was demonstrated in March–May 2026. A September 2026 private equity approach from Ares at A$2.50 per share was withdrawn after due diligence. --- ### Company's own description In its FY26 Directors' Report, MaxiPARTS describes its principal activities as distributing and selling commercial truck and trailer parts (the MaxiPARTS Operations segment) and distributing workshop consumables aimed mainly at automotive and commercial vehicle workshops (the Förch Australia segment). Its standard ASX boilerplate calls MaxiPARTS one of the largest suppliers of truck and trailer parts to Australia's road transport industry. Förch Australia is described as the exclusive Australian distributor of FÖRCH products. The FY25 Results Presentation positions the brand as one of Australia's leading *independent* commercial vehicle parts distributors. It highlights more than 30 branches, multiple customer-embedded on-site operations, over 162,000 parts available across the network (20,000 orderable online), two established private-label brands, and status as one of Australia's largest importers of aftermarket commercial vehicle parts. It also notes a Western Australian driveline rebuilding workshop that the company calls one of the largest dedicated heavy-vehicle driveline workshops in the country. ### Business model and revenue model All revenue is recognised as sale of goods at a point in time: A$274.4m in FY26, all classified as "sale of parts" (FY26 FS, Note 3(a)). There are no material subscription, licensing or service-contract revenue lines. The driveline workshop and on-site embedded operations are service-flavoured, but they are monetised through parts sales and are not separately disclosed. The revenue model is therefore approximately 100% product distribution. The economic engine is a classic aftermarket distribution model: **Buy:** source from OEM-genuine brand partners, aftermarket importers (notably a Japanese truck parts program acquired with Truckzone) and private-label manufacturers. Förch sources from Theo FÖRCH GmbH & Co KG in Germany. **Hold:** carry broad inventory (A$67.7m at 30 June 2026, about 25% of revenue) across a national branch and distribution-centre network. **Sell:** sell through branches (trade counter and delivery), embedded on-site stores at large fleet or mining customers, wholesale to resellers and trailer manufacturers, online ordering, and (at Förch) a direct field sales force plus a B2C e-commerce platform launched in 2025. Gross margin is about 34%. Computed from the FY26 P&L as revenue less cost of goods (changes in finished goods plus raw materials and consumables), it was 33.8% in FY26 and 33.6% in FY25. EBITDA margin is about 10.5%. Capital intensity is very low: capex was A$1.2m in FY26 (0.45% of revenue), and the company describes itself as "capex lite (<$1.5m)". Leases are the main fixed commitment: lease liabilities were A$32.2m at 30 June 2026. ### Value chain position MaxiPARTS sits in the independent aftermarket distribution layer, between global component manufacturers and brand owners upstream and transport operators, workshops and resellers downstream. It competes with OEM dealer parts channels (truck brand dealerships), other independent multi-site distributors, and specialist category players (brakes, suspension, driveline). Through Förch it also competes in workshop and industrial consumables, where it takes on direct-selling incumbents. ### Customer types and end-markets The FY25 Results Presentation shows revenue split across six customer types: B2B Sales, Fleet, Trailer OE, Workshop, Reseller and Cash. The chart values extracted were 23%, 47%, 5%, 12%, 5% and 8%. The exact mapping of each percentage to each label cannot be confirmed from the text extraction. The order suggests Fleet is the largest customer type at roughly 47%, but treat this as indicative. The FY26 Directors' Report describes wholesale customers as typically parts resellers and trailer manufacturers. Trade customers are road transport operators and commercial vehicle service and repair providers. End-markets include: - Line-haul and intrastate road freight. - Mining logistics, especially in WA (Port Hedland, Kalgoorlie). - Trailer original-equipment manufacturing. - Municipal and vocational fleets. - Automotive and commercial workshops (Förch). - Engineering and industrial trades (Förch). The company states it does not rely on any single customer (FY26 FS, Note 2(b)). ### Independent characterisation MaxiPARTS is best understood as a sub-scale but improving consolidator in a fragmented, cash-generative, non-discretionary aftermarket. Its FY22–FY26 history has three phases: 1. A margin-repair phase, exiting low-margin captive sales to the former trailer business. 2. An acquisition phase, adding Truckzone, Förch, Independant Parts and Förch Brisbane, funded by a A$16.2m equity raise and debt. 3. A de-leveraging and organic phase in FY25–FY26, featuring the Kalgoorlie greenfield store, growth in the Japanese parts range, Förch sales force expansion and inventory optimisation. Its strengths are a national footprint, a defensible exclusive distribution right at Förch, and strong cash conversion (116% in FY26). Its weaknesses are: - Scale: revenue of A$274m against peers such as Bapcor at A$1.9bn. - Low statutory returns: ROE about 8%. - Cyclical volume exposure to freight activity and diesel costs. - A thin, concentrated register in which NAOS holds about 22.6% and Perpetual about 9.4%. The aborted Ares approach in September 2026 confirmed private-capital interest in the asset. Its withdrawal after due diligence also introduced an information overhang.

Revenue$0.2B
Employees450
Market CapN/A
Founded1946
Victoria, Australia
MaxSight

Max Sight Group Holdings Limited

Premium
Information Technology

| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |---|---|---|---|---|---| | Employees at year end (headcount) | — | 64 | 78 | 64 | 47 | Max Sight Group is a micro-cap Hong Kong consumer-services company that for more than three decades has operated a network of automatic identity-document (ID) photo booths under the "Max Sight Photo" brand, positioned in metro stations, ID and visa application centres, universities, hospitals and shopping malls. Since October 2021 it has diversified into primary-care medical services through a small network of general-practice clinics branded "Max Medical", which in FY2025 overtook photography as the larger revenue line. The photo-booth franchise — historically high-margin and supplied by ME Group (Photo-Me) — is in structural decline as Hong Kong's Immigration Department digitises ID-photo capture through Personal Document Submission Kiosks and visa processes move online, and following the April 2025 expiry of a major government-site service contract. With revenue down 45% from its FY2023 post-COVID peak, rising losses and thin equity, the company was acquired in July 2026 by entrepreneur Li Xiangpu, whose plans beyond maintaining the existing businesses and listing remain undisclosed. --- ### Company's own description In its FY2025 Annual Report and FY2026 interim filings, the company describes itself as principally engaged in (i) providing photography services through automatic ID photo booths in Hong Kong (and, until 2025, Guangdong Province), and (ii) providing medical services by operating medical centres in Hong Kong, with a focus on general practice — primary care for acute illness and chronic disease management, routine health screenings, vaccinations and specialist referrals (IRA H1 2026). The company's website characterises it as a leading automatic ID photo-booth operator in Hong Kong and Guangdong, with a service promise summarised as precise validation and simple photography, backed by an "unconditional guarantee" of a free retake or full refund if a customer is dissatisfied with a photo (company website, accessed October 2026). The medical business is described as offering physical-examination plans, vaccination services, outreach doctor services, and sales of therapeutic services and wellness merchandise, alongside community medical benefit programmes (company website). ### Business model and revenue model | Revenue stream | Model | Recognition | FY2025 revenue (HK$ M) | Share of total | |---|---|---|---|---| | ID photo booth services (retail) | Pay-per-use self-service kiosks; cash and smart-card (Octopus-type) payment; site licences paid to landlords on fixed, revenue-share or higher-of basis | Point in time | Part of 21.190 | 47.6% (photography total) | | Sale of photo strips / consumables to an institutional customer | Product sale — replaced a service contract at government ID/visa sites after it matured in April 2025 | Point in time | Part of 21.190 | (included above) | | Medical consultation and related services | Fee-for-service GP consultations; vaccinations; health screening; medical cards via network agents; HK Government Elderly Health Care Vouchers | Point in time | 23.305 | 52.4% | Source: ARA FY2025 note 2; IRA H1 2026 notes 4 and 12. The revenue model is 100% transactional — no subscription or licensing revenue is disclosed. All revenue is recognised at a point in time (ARA FY2025). No single customer exceeded 10% of revenue in FY2024, FY2025 or H1 2026 (ARA FY2025; IRA H1 2026). ### Value-chain position **Photography:** Max Sight sits at the operator/retail end of the value chain. It does not manufacture booths; booths and consumables have historically been sourced from ME Group International plc (formerly Photo-Me International plc), a relationship dating from 1993 and formalised in a Master Supply Agreement dated 4 August 2023 covering FY2023–FY2025 with annual caps of HK$1 M for booths and HK$3 M for consumables (AR 2023, AR 2025). Its key upstream dependency is landlords/licensors (MTR stations, government buildings, malls, universities) that grant booth sites. **Medical:** The Group owns and operates clinic premises and engages doctors partly through consultancy companies that are also minority shareholders in clinic-holding subsidiaries (Echo Bay Consultant Company Limited holds 19% of Speed Dragon Development Limited; Mingway Health Limited holds 20% of Wealthy Dragon Development Limited) and are paid a fixed monthly fee plus profit share (Company announcement, 25 Sep 2026). ### Customer types and end-markets | End-market | Customer type | Key demand drivers | |---|---|---| | ID photography (Hong Kong) | General public needing passport, HKID, visa, travel permit, student and licence photos | Document renewal cycles; travel demand; immigration schemes (e.g., Top Talent Pass Scheme from 2022–23); government document digitisation (negative) | | ID photography (Guangdong) | General public | Largely displaced by PRC online applications with digital photos and face recognition (ARA FY2025) — operations wound down by end-2025 | | Primary care (Hong Kong) | Walk-in patients, medical-card holders via network agents, elderly using healthcare vouchers | Seasonal influenza; HK Primary Healthcare Blueprint; Hospital Authority fee reform effective 1 Jan 2026 | ### Independent characterisation Max Sight is best understood as a sub-scale, family-built, cash-generative-at-peak niche operator that has been caught between two structural shifts: (1) the digital substitution of physical ID photos, which is eroding a historically high-margin core; and (2) an unsuccessful attempt to scale a diversification into primary care, which, while stable at roughly HK$22–23 M of revenue, generates segment margins in the mid-single digits and has not expanded beyond its existing clinics since 2023 because "no suitable project was identified" (ARA FY2025). The July 2026 sale of 75% of the company at HK$0.0875 per share — a 22% discount to the prior closing price but a 376% premium to book value — is consistent with a transaction priced substantially on the value of the GEM listing platform itself (JA 27 Jul 2026). Post-transaction, the strategic direction is effectively a blank page pending the new controller's review.

Revenue$0.0B
Employees45
Market CapN/A
Founded1989
P.O. Box, Cayman Islands
Matsa

Matsa Resources Ltd

Premium
Information Technology

Matsa Resources is a Perth-based gold junior that made the transition from explorer to small-scale producer in 2025. Its vehicle is the Devon Pit, a short-life open pit inside its 100%-owned, ~450 km² Lake Carey Gold Project in Western Australia's Laverton Tectonic Zone. Lake Carey sits beside AngloGold Ashanti's Sunrise Dam and Gold Fields' Granny Smith and Wallaby operations. Matsa reports a 949koz JORC resource (11.9Mt @ 2.5 g/t Au) and an exploration target of 643koz–1.85Moz at Fortitude North. It also holds an A$101M-headline option agreement under which AngloGold may acquire most of Lake Carey by 20 December 2026. In September 2026 the strategy was disrupted: Devon was suspended, the contractor appointed receivers, and two subsidiaries entered administration. Secured debt to Deutsche Balaton has risen to about A$38M. The investment case now rests on whether AngloGold exercises its option, how the Devon dispute resolves, and the Fortitude North drilling results. --- **Company's own description (website, 2026).** Matsa describes itself as a growth-driven gold producer focused on development opportunities in the Lake Carey region. It says it has already established mining capability through a multi-campaign operation at the Devon Pit. It aims to build on its existing ~1Moz resource base through aggressive exploration in 2026–2027, targeting 2–3Moz in resources. Elsewhere it describes itself as an ASX-listed exploration and gold mining company operating south of Laverton in the north-eastern Goldfields of Western Australia, with a Thai-based office and landholding prospective for lithium and base metals. **Independent characterisation.** Matsa is best understood as a pre-scale, single-asset gold explorer-developer with an opportunistic, contractor-dependent mining overlay. It owns no processing plant and no mining fleet. Its 2025–26 production model was entirely outsourced: **Mining:** Blue Cap Mining Pty Ltd (BCM), under a March 2025 Mining Services Agreement. BCM received a 20% profit share, and its affiliate Blue Capital Equities provided up to A$6M of working capital. **Processing:** FMR Investments' Greenfields mill near Coolgardie, under a toll-milling agreement priced as a fixed fee per tonne of throughput. Ore was trucked roughly 300 km by road train and processed in discrete campaigns of about 50kt. **Refining and sale:** Gold doré was delivered to the Perth Mint for refining and sale at spot. **Revenue model.** There is no service, subscription or licensing revenue. The mix is close to 100% commodity product (gold), plus lumpy transactional receipts from asset optionality. **Value-chain position.** Matsa operates upstream: tenement holding, exploration, resource definition and, at Devon, mine ownership with outsourced execution. It captures the commodity margin only after toll-milling, haulage, contractor profit share and royalties. That leaves thin economics at small scale, which the 2026 grade and dilution problems exposed. **Customers and end-markets.** The sole customer is the Perth Mint, as refiner and buyer. The end-market is the global gold market. Spot gold was A$5,781/oz on 30 June 2026 (Matsa June 2026 quarterly), a historically high price that underpinned the Devon restart decision. **Secondary assets.** - Thailand: lithium-mica (lepidolite and polylithionite) and base-metal exploration applications lodged with Thailand's Department of Mineral Resources. There is a Thai office and management team. - Lake Rebecca: 20% interest, with Bulletin Resources Limited holding 80%. - Regional Western Australian tenements prospective for gold, lithium and rare earth elements.

RevenueN/A
Employees20
Market CapN/A
Founded2003
Perth, Australia
Matrix

Matrix Holdings Limited

Premium
Information Technology

Matrix Holdings is a controlled, Hong Kong-headquartered, Bermuda-incorporated micro-cap that designs, manufactures and distributes plastic, die-cast and plush toys and, secondarily, lighting products, with all manufacturing concentrated in three plants in Da Nang, Vietnam. Its model blends contract manufacturing for third-party brand owners (OEM), licensed design-and-make programmes (ODM — e.g., CAT construction-vehicle toys, SpongeBob SquarePants, Teenage Mutant Ninja Turtles) and proprietary brands (OBM — e.g., Gazillion bubbles, Fart Ninjas, Mighty Fleet, Powershots), principally through its US arm Funrise. Roughly 63% of revenue is sold into the United States. After a four-year contraction in which revenue fell from HK$1.08bn (FY2021) to HK$457M (FY2024) and cumulative attributable losses exceeded HK$560M (FY2023–FY2025), the group returned to a small profit in H1 2026 on a new major OEM customer. It carries a going-concern material-uncertainty emphasis, depends on loans from its chairman, and holds a large, stalled Vietnamese property-development position. --- ### Company's own description The annual report describes the group as a long-established manufacturer of plastic, die-cast and plush toys with a vertically integrated process spanning mould-making, manufacturing and design, and as a manufacturer of lighting products, currently operating three plants in Vietnam [AR25]. It notes that the Shelcore toy companies, the Funrise Group and two overseas lighting companies were merged into the group in 2005, 2007 and 2017 respectively [AR25]. The company's statutory note states that the holding company's principal activity is investment holding and that subsidiaries are engaged in manufacturing and trading of toys and lighting products and in property development [FR25]. ### Independent characterisation Analytically, Matrix is three businesses wrapped in one listing: 1. **A Vietnamese contract-manufacturing platform (OEM).** The Da Nang plants (aggregate factory floor area ~122,722 m²) [AR25] make product to the specifications of other toy companies and retailers. This is the business that drove the H1 2026 turnaround: management attributes the 28.2% revenue increase to securing a new major customer and higher OEM volumes [IR26]. OEM economics are volume- and utilisation-driven: fixed-cost absorption is the swing factor, which explains the extreme operating leverage visible in FY2023–FY2025. 2. **A US branded/licensed toy marketer (OBM + ODM) — the Funrise Group.** Funrise (Van Nuys-area, California heritage; Funrise Inc. founded 1987 per director biography of Shirley Marie Price) [AR25] owns brands such as Gazillion and runs licensed programmes (CAT, SpongeBob SquarePants, TMNT). This layer carries distribution and selling costs (HK$146.2M in FY2025, 30.3% of revenue) and royalty expenses (HK$37.2M in FY2025, 7.7% of revenue) [FR25]. It gives Matrix shelf presence at US mass retail but also exposes it to licence-renewal risk, inventory obsolescence (HK$23.0M write-down in FY2025) and royalty minimums. 3. **A Vietnamese property-development option.** A reportable "Property development" segment holds HK$239.6M of segment assets at 31 Dec 2025 (37.6% of group total assets) and HK$241.3M at 30 Jun 2026, but has generated no revenue [FR25], [IR26]. Progress on land acquisition in Da Nang has been delayed by Vietnamese government restructuring, and land-use-right certificates have not been obtained [AR25], [IR26]. ### Revenue model | Revenue model element | Description | Disclosure status | |---|---|---| | Product sales (toys) | Point-in-time sale of manufactured/traded toys; HK$449.8M in FY2025 (93.1% of revenue) | [FR25] | | Product sales (lighting) | HK$33.5M in FY2025 (6.9%), nearly doubled from HK$16.9M | [FR25] | | Over-time revenue | HK$7.5M recognised over time in FY2025 (contract assets appear for the first time: HK$3.5M) — consistent with custom OEM manufacturing contracts | [FR25] | | Subscription / licensing income | Negligible; royalty income HK$29K in FY2024, nil in FY2025 (Matrix is a licensee, not a licensor) | [FR25] | | Property sales | None to date | [FR25], [IR26] | | OEM / ODM / OBM split | Not publicly disclosed in HK$ terms | — | ### Value-chain position, customers and end-markets Matrix sits at the manufacturing and brand-marketing stages of the toy value chain: it buys resins, die-cast alloys, fabrics and electronic components, converts them in Vietnam, and either ships FOB to OEM customers or sells finished branded/licensed goods into retail. Customer concentration is severe: in H1 2026, three US customers accounted for 22.1%, 17.6% and 17.1% of group revenue (56.8% combined), and in H1 2025 two US customers accounted for 26.6% and 20.0% [IR26]. Customer names are not disclosed. End-markets are consumer toy retail in the US (≈63% of FY2025 revenue), Europe (≈17%), Canada, Australia/New Zealand, Mexico and South America [AR25].

Revenue$0.1B
Employees2,200
Market CapN/A
Founded1993
Hamilton HM, Bermuda

Page 99 of 482

1…9899100…482

Page 99 of 482

Go to page
Deloitte logo
Accenture logo
Oracle logo
PWC logo
EY logo
Honeywell logo